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This research investigated the repercussions of aberrant P AX3 re­
expression in cutaneous malignant melanoma (CMM). The transcription 
factor encoded by P AX3 is amongst the first expressed in the embryo, with 
a principal role in the development of the melanocytic lineage. We theorised 
that abnormal re-expression of FAX3, consistently observed in CMM as 
compared to normal melanocytes, is linked to progression of CMM. 
Previous studies have stated that expression profiles of P AX3 in CMM 
demonstrate predominant generation of a protein encoded by exons 1-9 
(P AX3D) utilising cryptic splice sites in post-transcriptional pre-mRNA 
splicing. By contrast, normal human skin demonstrates low level generation 
of PAX3C (encoded by exons 1-8). Using RT-PCR based techniques and 
immunohistochemistry, we present original evidence of Pax3c, Pax3d 
mRNA and protein expression in normal murine embryogenesis and 
melanogenesis, identifying a conserved role for the Pax3d protein in 
transcriptional regulation of the murine melanoblast. Furthermore, to 
identify a role for Pax3 in adult skin, we used a reliable time-scale for the 
strict coupling of melanogenesis to active hair regrowth; Pax3c and Pax3d 
expression profiles were assessed during depilation experiments which 
induced murine melanocytic stem cells to proliferate, migrate into the hair 
cortex and differentiate in order to produce melanin for new hair. Results 
indicate that strict temporal expression of Pax3d may be linked to either 
melanoblast proliferation or migration in early melanogenesis thus 
supporting a possible role for P AX3 D in the tumourigenesis of CMM. 
Differences in the structure of the C-terminal region of the 
transcription factors P AX3C and P AX3D influence transcriptional 
activation of downstream target genes via protein-protein interactions. As 
P AX3 is known to up-regulate the gene encoding micropthalmia-associated 
transcription factor (MITF), we sought to establish a possible link between 
IV 
aberrant P AX3 expression and regulation of MITF in CMM by comparison 
of Pax3c, Pax3d and Miif-m mRNA expression in murine embryogenesis and 
melanogenesis. Results indicate that while Miif-m expression may be reliant 
on Pax3c expression, Pax3c expression is not solely linked to Miif-m 
upregulation. Moreover, no apparent correlation appears between Miif-m 
and Pax3d expression as random inverse and overlapping expression of 
these genes was observed during murine embryogenesis and adult hair 
regrowth. Finally, a link between Pax3 and c-Kit was sought. Knowing that 
loss of the c-Kit tyrosine kinase receptor occurs in CMM and that PAX3 
functions as a gene repressor, we analysed mRNA profiles of Pax3c, Pax3d 
and c-Kit in depilation experiments to investigate possible inverse 
correlations in gene expression. Although the c-Kit promotor sequence 
reveals potential binding sites for Pax3, our results indicate that loss of c-KIT 
expression in CMM is not potentially linked to aberrant P AX3 expression. 
V 
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1 
INTRODUCTION 
1.1 INTRODUCTIO,�----------------
As far back as 1910, cancer was suspected to be primarily a genetic 
disease; undeniably, the past century has witnessed the unravelling of 
numerous genetic events involved in the pathogenesis of the neoplastic cell. 
The basis of this research lies in the supposition that gene transcription 
factors that function to regulate development within the embryo are often re­
expressed in tumourigenesis and therefore able to be selectively utilised by 
neoplastic cells for cancer progression. In line with this supposition, CMM 
arises within cells of neural crest origin, a lineage in which P AXJ is a principal 
regulator of progenitor cell migration and differentiation. This, combined with 
the observation that PAXJ is over-expressed in CMM (in contrast to virtually 
no expression in normal skin or benign naevi) led to the hypothesis that the 
developmental role of P AXJ may be re-activated in CMM and thus contribute 
to neoplastic progression of melanocytes. The aims of this research therefore 
became to investigate normal Pax3 expression profiles during key stages of 
melanocytic development in order to more clearly hypothesise possible 
repercussions of aberrant re-expression in CMM. Correlations were sought 
between Pax] expression and the expression of c-Ki,t or Miif, two potential 
downstream targets of Pax3 to examine the consequences of aberrant PAXJ 
expression in CMM. 
2 
2 
LITERATURE 
REVIEW 
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"Science increases our power in proportion to the diminishing of our pride,, 
Claude Bemard 
In an effort to understand the implications of increased P AX3 
expression in CMM, this literature review focuses on development of 
melanocytic cells from the neural crest, melanocytic function following 
differentiation and pigment production, aetiologies and pathogenesis of 
CMM, P AX3 / Pax3 involvement in embryogenesis and finally, key proteins 
thought to be activated by PAX3 and implicated in the progression of CMM. 
The scope of the review is wide-ranging; it has led to a publication (Blake & 
Ziman, 2003) which generated international interest and formed the 
foundation on which the discussion is based. 
2.1 MELANOCYTIC CELLS-------------
Melanocytes are specialised pigment producing cells located primarily in 
the epidermis, hair follicle, cochlea and choroid of the eyes. Production of 
melanin pigment within each subpopulation of melanocyte is associated with 
varying function according to the tissue. For example, in the stria vascularis 
(the lateral wall of the cochlear duct), melanin pigment is thought to play a 
role in hearing (Mou et al, 1997; Takeuchi & Ando, 1997; Masuda et al, 1994) 
while in the choroid of the eye, melanin is essential for the maintenance of 
vision (Hu et al, 2002). This review, however, focuses on epidermal 
(cutaneous) and hair follicle (follicular) melanocytic cells, from their 
specifications as melanoblasts (melanocytic stem cell) to their differentiation 
into melanocytes (cells capable of melanin production). In order to unravel 
possible repercussions of the aberrant expression of P AX3 in CMM, review 
of the literature initially focused on the normal development of melanocytes. 
2.1.1. Melanocytic Development 
Due to lack of human embryonic tissues or models for study of 
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melanocytic development, much of what is known about the migration and 
differentiation of melanocytic cells has been studied in a murine animal 
model. Throughout the review, reference will be made to melanocytic 
development in mice, although it differs slightly from human melanocyte 
development. Where necessary, key differences are noted. 
In mice, neural crest cells become committed to the melanoblast 
lineage at around embryonic day 8.5 (E8.5) and begin migration dorsolaterally 
toward the ventral midline and into the dermis at around day E10.5 (Mayer, 
1973). An early study by Mintz (1967), used groups of coloured mice, 
containing two alternatively pigmented melanocytic genotypes to reveal that all 
melanocytes in murine coats are clonally derived from a fixed, small number 
of primordial melanoblasts that proliferate and migrate to prospective regions 
of the dermis in a specific pattern, as described by Mintz: 
"The animals are dramatically striped, with a series of broad transverse 
bands of alternating colors extending down the full length of head, body, 
and tail. The sharp mid-dorsal separation indicates that the two sides are 
established autonomously, without physical contiguity, so that a left and 
a right member are actually present. Each cell appears to proliferate 
laterally, and to a lesser extent longitudinally, to fill the available space 
between epidermis and dermis, bounded on each side by neighboring 
clones. There are 17 successive bands down each side of an animal. The 
head has three per side. On each side, there are 6 bands on the body, and 
8 on the tail. The simplest explanation for these bands, consistent with 
all known facts of pigmentary ontogeny, is that each is a clone of 
melanoblasts, descended mitotically from a single cell." (Mintz, 1967) 
That melanocytes of the murme coat are descended from a small 
number of primordial melanoblasts whose progeny proliferate, migrate and 
regionalise within specific regions of the body, may be analogous to human 
melanocytic proliferation and migration; this will be further discussed in 
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relation to germline pathogenesis of human melanocytes such as is seen m 
giant congenital naevus (see page 29). 
Following regionalisation of melanoblasts in the murine dermis, during 
a specific window of time at around E12.5-13.5, melanoblasts enter the 
epidermis synchronously and proliferate extensively (Yoshida et al., 1996). 
Subsequently, at around E15, a subpopulation migrates toward the developing 
hair germ (Hirobe, 1984). Here, a fraction of melanoblasts remain within the 
follicle as stem cells, while others begin to terminally differentiate at around 
E14, with pigmentation induced around 2 days later (Hirobe, 1984). After 
birth, most epidermal melanocytes, except those of hairless areas such as the 
ears and tail, undergo apoptosis (Hirobe, 1984) leaving only melanoblasts and 
melanocytes of the hair follicles to produce pigmentation of the coat in mice. 
In human melanocytic development, melanoblasts are found in the 
epidermis at 9-11  weeks of gestation, prior to the development of the hair 
germs (Hashimoto, 1991). Most of the primary hair germs over the skin 
surface develop at around four months of gestation (Hashimoto, 1970). At 
this point, a subpopulation of epidermal melanoblasts migrates into 
developing hair matrices before maturation into melanin producing cells; it is 
currently unknown, however, whether a fraction of these melanoblasts remain 
in the human follicle as stem cells such as is seen in mice. In contrast to 
murine melanocytes, both populations of human follicular and epidermal 
melanocytes remain active throughout postnatal life in the pigmentation 
process, although activity diminishes with aging. 
2.1.2 Normal melanocyte morphology and histology 
Visualised by bright light microscopy, normal melanocytes have a 
rounded cell body with characteristically clear cytoplasm and small round 
nucleus (Figure 2.1); their primary function is to produce and distribute 
melanin pigments to adjacent keratinocytes. Visualised by electron 
6 
microscopy, long, fine cytoplasmic dendrites can be seen extending from the 
soma of the melanocyte (Figure 2.2). 
Figure 2.1. Human Epidermis. 
Light microscopy showing normal epidermal melanocyte (indicated by arrow) situated 
at the dermal/ epidermal border. Note the characteristic round cell body, round nucleus 
and clear cytoplasm. 
Figure 2.2. Melanocyte. 
Electron microscopy showing melanocyte 
with fine dendritic processes. 
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In human skin, there is an orderly ratio of one melanocyte per several 
keratinocytes, called the epidermal-melanin unit. Once transferred from the 
melanocyte, melanin pigment accumulates above the nuclei of keratinocytes 
within the unit (Figure 2.3). Proliferating and the least mature post-mitotic 
keratinocytes are in the basal layer of the epidermis, adjacent to the dermis. 
Here, melanin is thought to protect mitotic cells from the ionising effects of 
UV irradiation. 
Figure 2.3. Epidermal-melanin unit. 
Melanocytes distributing melanin among adjacent kerat:inocytes 
of epidermal-melanin unit. Arrows indicate cell bodies of the 
melanocytes. 
2.1.3 Melanogenesis in the Hair Follicle 
Melanogenesis refers to the complex process leading to the production 
of pheo- and eumelanin pigments within melanocytic cells. An intensely 
studied form of melanogenesis occurs in conjunction with the growth of new 
hair (both in humans and in mice). As the hair follicle cycles through stages of 
active growth (anagen), regression (catagen), resting (telogen), and shedding 
(exogen), pigment cells also cycle through periods of proliferation, migration, 
differentiation and apoptosis (Miiller-Rover et al., 2001) (Figure 2.4). 
8 
'l'ELOGEN 
Figure 2.4. Hair Follicle Cycling. 
Diagram depicting hair cycling through stages of 
anagen (active growth), catagen (regression) and 
telogen (resting). 
In mice, the hair follicle contains at least two distinct populations of 
melanocytes and melanoblasts; one melanogenic, the other not, respectively 
(Tobin et al., 1 995; Tobin & Bystryn 1 996; Nishimura et al., 2002) . 
Melanogenically active melanocytes are located in the hair cortex where they 
are distributed in close contact with the basal lamina, separating the cortex 
and the dermal papilla (Figure 2.5) .  These cells express tyrosinase mRNA and 
actively produce pigment during late anagen (Slominski et al. 1 991 ;  Ortonne & 
Prota 1993); in murine hair, pigment is passed from melanocytes to follicular 
kerytinocytes via dendritic processes (Staricco, 1 962; Morrelli et al., 1 991) .  In 
the stages of follicular catagen or exogen, cortex melanocytes have been seen 
to retract dendritic extensions before undergoing apoptosis (Tobin et al., 
1 998) .  In mice, replacement of these lost cortex melanocytes occurs by 
proliferation of a distinct, small population of melanoblasts that remain in an 
undifferentiated state, as a stem cell population, within an area known as a 
"niche" (Nishimura et al., 2002) . This niche is located in the outer root sheath 
of the lower permanent portion of the hair follicle, just below the bulge area 
where the arector pili muscle is attached (Nishimura et al., 2002) . Melanoblasts 
do not produce melanin or melanosomes and are always maintained in this 
bulge area (Nishimura et al., 2002) . Furthermore, in vitro studies demonstrate 
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that amelanotic melanoblasts in anagen have extensive proliferative potential. 
By contrast, cortex melanocytes are not cultured successfully, suggesting that 
these cells are more terminally differentiated (Tobin et a/. 1995; Tobin & 
Bystryn 1996). 
Figure 2.5. Hair Follicle. 
Within the hair follicle, fully differentiated melanocytes 
capable of melanin production are located within the 
cortex, above the dermal papilla. 
As the hair follicle undergoes transition from telogen to anagen, 
melanoblasts migrate out of the stem cell niche to proliferate. At least one of 
the daughter stem cells remain in the bulge area while the other migrates into 
the developing hair germ where it eventually localises in the cortex, further 
proliferates and differentiates into a melanocyte. The reserve of melanocytic 
stem cells within the niche is thought responsible for the continued 
proliferation of both follicular and cutaneous melanocytes in the mouse 
(Nishimura et a/., 2002). In this research, proliferation of murine melanocytic 
stem cells from the follicular niche was induced by depilation of normal 
murine skin in order to assess Pax3 mRNA expression profiles during 
proliferation and migration of melanoblasts. 
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2.1.4 Melanogenesis in the Skin 
In human skin, cutaneous melanocytes are located in the epidermis 
within the basal layer (adjacent to the basement membrane) where they adjoin 
to epidermal keratinocytes via dendritic extensions in order to pass 
cytoplasmic melanosomes. It has been estimated that the ratio of melanocyte 
to keratinocyte is 1 :40, although thfr- ratio varies according to the area of the 
body. Melanisation patterns of human skin reveal that some areas with 
concentrated pigmentation are not exposed to UV; this is linked to an 
alternate function for melanin as an antimicrobial for skin (Mackintosh, 2001). 
In transgenic mice bred to retain functional cutaneous melanocytes, 
analysis of induced proliferation has shown that following apoptosis of 
cutaneous melanocytes, melanocytic stem cells migrate out of neighboring 
hair follicles to proliferate. These cells then migrate further along routes 
connecting the follicular outer root sheath and epidermis toward their final 
destination within an epidermal-melanin unit (Lei et al, 2002; Nishimura et al, 
2002). Similarly, human studies have shown that following treatment of skin 
in disorders such as vitiligo (a condition in which skin lacks pigmentation due 
to loss of functional melanocytes), re-pigmentation follows a pattern where 
pigmented spots first appear in concentric rings surrounding the hair follicle. 
With time, these rings enlarge and eventually fuse to recolour the skin 
(Nishimura et al, 2002). These two studies imply that follicular melanocytic 
stem cells are associated with a continued renewal of lost cutaneous 
melanocytes, although research has not demonstrated evidence of a stem cell 
population in the human hair follicle to date. 
2.1.5 Human Melanogenesis with UV Exposure 
Melanin plays an important role in the protection of keratinocytic 
cellular DNA by forming a protective envelope around the cell nucleus 
(Valverde et al, 1995). It absorbs free radicals generated in the cytoplasm and 
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shields the nucleus from various types of ionizing radiation, including ultra­
violet (UV) light. In the event of extreme or repeated exposure to UV 
irradiation, increased synthesis of melanin is evidenced by "tanned" skin. 
Exposure of melanocytes to UV irradiation results in a highly complex 
process of DNA repair (Eller et aL, 1994; Barker et aL, 1995; Winter et aL, 
2001), upregulation of autocrine and paracrine cytokines (Abdel-Malek et al., 
1995; Imokawa et aL, 1996) and induction of mitosis (Kawaguchi et aL, 2001). 
Signalling between UV exposed keratinocytes, melanocytes and fibroblasts 
results in an increase in the number, size and dendricity of melanocytes 
(Balaban et al., 1988; Grichnik et aL, 1998). Studies have shown that the skin 
has precise mechanisms in place both for the prevention of uncontrolled UV 
induced melanocytic apoptosis (Allsopp et aL, 1993) and uncontrolled 
proliferation within the epidermis (Bacharach-Buhles, 1999). 
Controversy has existed as to whether increased numbers of 
melanocytes following UV exposure is due to an increase of mitotic activity of 
cutaneous melanocytes or due to induction of melanoblasts from a stem cell 
population. Rosdahl & Szabo (1978) reported that cell division of established 
cutaneous melanocytes is responsible for a 4-6 fold increase in melanocyte 
numbers during irradiation. However, only 65-80% of their increased 
population were from labelled precursors; they had no explanation for the 
origin of the further 20-35% neo-melanocytes. 
Using transgenic mice in which cutaneous melanocytes function 
postnatally, murine studies have shown that a high percentage of cutaneous 
melanocytes undergo apoptosis in response to intense UV exposure. This, 
along with cytokine signaling via epidermal keratinocytes in response to 
irradiation, promotes migration of melanoblasts from the outer root sheath of 
hair follicles (Kawaguchi et aL, 2001; Lei et aL, 2002). Increases of melanoblasts 
(not yet capable of melanin production) have been seen in the epidermis on 
the first day following UV exposure. Around the fifth day following exposure, 
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differentiation of the melanoblasts was evident and resulted in four times as 
many melanin producing cells as compared to normal control skin 
(Kawaguchi et al., 2001). These studies indicate that intense UV exposure may 
overwhelm normal mitotic capabilities of cutaneous melanocytes leading to 
apoptosis and further recruitment of stem cells from the niche in order to 
replace lost cells. 
Undeniably, primary causes for transformation of the melanocytic cell 
to neoplasia are numerous and are continuously being investigated. While 
many theorise that mutagenic disturbances following intense UV exposure 
occur within melanin-producing melanocytes, this study supports the 
possibility of UV mutagenesis within mitotic stem cells or post-mitotic 
melanoblasts and discusses possible repercussions of this occurance. 
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2.2 PRECURSORS OF CMM 
Although exposure to UV 1s a principle factor involved in the 
acquisition of CMM from benign melanocytic naevus, several studies detail 
neoplasia arising due to occurrence of giant congenital melanocytic naevus 
and dysplastic naevus syndrome. 
2.2.1 Benign melanocytic naevus 
A large percentage of CMMs are known to anse from cutaneous 
melanocytes within normal skin (Barnhill & Mihm, 1993), however, 40-50% 
of CMMs are thought to develop from benign melanocytic naevi (Lopansri & 
Mihm, 1979). A benign melanocytic naevus is thought to arise as a 
consequence of excessive ultraviolet exposure leading to mutagenesis and 
mitogenesis of cutaneous melanocytes. UV mutagenesis of melanocytic cells 
can lead to loss of tumour suppressor genes, low-level microsatellite instability 
and a reduction in expression of mismatch repair proteins (Alvino et al., 2002; 
Hussein et al. , 2002; Hussein & Wood, 2003). In any event, these atypical 
melanocytes are referred to as naevus cells and they usually develop between 
the first and thirty-fifth year of life, undergo specific stages of maturation and 
finally senesce (Lund & Stobbe, 1949). 
In contrast to normal melanocytes, naevus cells are oval or cuboidal 
with large, often vesicular nuclei and clearly outlined cytoplasm; although they 
are capable of melanin production, they follow a divergent path of 
differentiation eventually expressing proteins similar to those of Schwann cells 
(Reed et al., 1999). Within the skin, collections of naevus cells aggregate to 
form nests at rete ridges (where the epidermis invaginates toward the dermis) 
(Figure 2.6). 
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Figure 2.6. Nest of melanocytic naevus cells. H&E staining. X400 
Arrow indicates nest of atypical naevus cells located at the rete ridges of the 
epidermis. 
At this stage, a benign melanocytic naevus is classified as a 'junctional 
naevus'; typically, naevus cells do not extend into the dermis. However, as 
naevus cells continue to proliferate and differentiate, post-mitotic cells acquire 
the ability to migrate into the dermis. At this stage a benign melanocytic 
naevus is classified as 'compound' with naevus cells spanning both the 
epidermis and dermis. From this stage, naevus cells become separated from 
the epidermis by connective tissue, cease to proliferate and eventually senesce 
(Reed et al. , 1999). 
It is hypothesised that CMM may anse from nests of benign 
melanocytic naevi, either from a naevus cell or from melanocytes adjacent to 
or within nests of naevi. Fortunately, most benign melanocytic naevus cells 
undergo transition from proliferative to non-proliferative, rendering them 
harmless to the carrier. An important phenotypic characteristic of benign 
naevus cells is loss of telomerase activity during their transition from 
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proliferative to non-proliferative (telomerase activity is necessary during cell 
proliferation to prevent telomere attrition). This is in stark phenotypic 
contrast to CMM, where neoplastic cells retain the ability to proliferate due to 
increased telomerase activity (Rudolph et al., 2000). 
This begs the question, do benign naevus cells diverge from the benign 
differentiation pathway to become CMM; for example, is each cell able to 
change from one pathway to the other? While this theory is feasible, an 
alternate explanation for phenotypic differences between benign melanocytic 
naevi and CMM may be that mutagenesis of mitotic or post-mitotic cells 
results in cellular differentiation down one pathway or the other, both being 
mutually exclusive and randomly occurring within the cell. 
2.2.2 Congenital N aevi 
Another precursor of CMM is thought to be a congenital naevus, 
present at birth and affecting 1-2% of neonates (Walton et al., 1976). A 
congenital naevus appears as a brown or black round or oval plaque, often 
associated with overgrowth of hair (Figure 2. 7). The naevus may be small 
(15mm), medium (15-199mm) or giant (>200mm) and comprised of the 
following cell types in any combination: melanocytic naevi, neuroid naevi 
(naevus cells expressing nerve sheath proteins), blue naevi, and/ or cellular 
blue naevi. 
While a small congenital naevus is associated with a 3% risk of 
transformation, a giant congenital naevus has a 15% risk of developing into 
CMM before the age of pubescence (Dellon et al., 1976). Furthermore, 
statistics have shown that 40% of CMM cases seen in children arise from 
giant congenital naevus (Dellon et al., 1976; Quaba & Walllace, 1986). 
Although there is no known genetic contribution to date, it has been 
suggested that a number of cases of congenital naevus may be determined by 
an autosomal dominant gene of variable expressivity (Goodman et al., 1971). 
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As melanocytes of human skin are thought to be clonally derived from a small 
population of primordial melanocytic stem cells which migrate in a standard 
pattern such as the murine melanocytes seen in Mintz' work (see pg. 17), 
mutagenesis of mitotic stem cells or post-mitotic primordial melanoblasts may 
be a plausible explanation for development of giant congenital naevi (Figure 
2.7). 
Figure 2. 7. Congenital melanocytic naevus. 
Infants with giant congenital naevus. Removal of the 
naevus requires several extensive surgeries. 
2.2.3 Dysplastic naevus syndrome 
10% of CMM cases are familial and suggest an inherited predisposition 
(Fountain et al, 1990). One such predisposition may be dysplastic naevus 
syndrome, an autosomal dominant inherited disposition in which affected 
individuals develop 10-100 large naevi following puberty (Haley et al, 
2000)(Figure 2.8). 
In comparison to benign melanocytic naevus cells, cells of a dysplastic 
naevus are increasingly atypical relative to normal melanocytes. Following a 
progression of developmental stages similar to benign naevus cells, the 
dysplastic naevus cells divert at migration into the dermis. Here cells continue 
to proliferate, synonymous with increasing atypia, hyperplasia, hypertrophy 
and dysplasia. Histological criteria for diagnosis of dysplastic naevus syndrome 
are lamellar and concentric dermal fibroplasia, presence of dermal 
lymphocytic infiltrate and elongation of rete ridges (Elder et al, 1982; Kraemer 
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& Greene, 1985) . Furthermore, dysplastic naevus cells have significantly larger 
nuclei, consistant with a hyperdiploid or tetradiploid DNA content. 
Figure 2.8. Dysplastic Naevus Syndrome. 
Note the number of naevi present on the trapezoidal region of the back. 
Arrows indicate suspect melanomas. Circled naevi are examined for 
growth and color changes over time. Persons with this syndrome are 
considered highly susceptible to development of CMM. 
Dysplastic naevus is known to be a precursor of many cases of CMM; 
in fact persons inheriting dysplastic naevus syndrome are highly susceptible to 
CMM (Greene et al., 1 985; Bale et al., 1 986) .  Two principal loci known to be 
associated with dysplastic naevus syndrome are at 1 p (the gene locus called 
CMM1) and 9p (the gene locus called CMM2). Through multipoint linkage 
analysis, Bale et al. (1 989) mapped CMM1 to 1p36. Patients carrying a 
mutation at this locus have distinctive characteristics of the skin, closely 
resembling xeroderma pigmentosum (a syndrome in which individuals possess 
a defect in DNA-repair mechanisms) . It has recently been shown that reduced 
DNA-repair ability combined with presence of dysplastic naevi syndrome is 
strongly associated with risk of CMM and may contribute to susceptibility to 
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sunlight-induced CMM (Landi et al., 2002) . 
The CMM2 locus at 9p21 contains several candidate genes for CMM 
(Puig et al., 1995) . Chromosome region 9p21 is involved in homozygous 
deletions in more than half of all melanoma cell lines (Kamb et al., 1994). The 
region was found to contain the gene CDKN2A which encodes an inhibitor 
of cyclin-dependent kinase-4 (CDK4) (Serrano et al., 1993; Kamb et al., 1994) . 
Complexes formed between CDK4 and cyclins are involved in the control of 
cell proliferation during the G 1 phase. In familial melanomas it has been 
established that a mutation in the CDKN2A gene leads to a marked increased 
risk for CMM, although a number of 9p21-linked kindred lack germline 
coding mutations in CDKN2A (Loo et al., 2003) . 
In summary, deficiency in mutation excision repair systems is strongly 
linked to development of CMM, particularly when an affected individual is 
subjected to extreme UV exposure. CMM arise from normal skin or an 
existing benign melanocytic naevus; persons possessing either congenital 
naevus or dysplastic naevus are at an increased risk. In the case of congenital 
naevus, risk of developing CMM has not been linked to a particular mutation. 
By contrast, in dysplastic naevus syndrome, mutations in CMM1 at 1 p36 or 
CMM2 at 9p21 have been identified; however, many persons with dysplastic 
naevus syndrome do not possess either mutation and yet develop CMM while 
many persons with dysplastic naevus syndrome harbouring a known mutation 
in either 1 p36 or 9p21 do not develop CMM. Although mutations in PAX 
genes are associated with many forms of cancer (Bennicelli et al., 1996; Iida et 
al., 1996; Kroll et al., 2000) , these studies have demonstrated that causative 
mutations in CMM are not associated with P AX3. 
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2.3 CUTANEOUS MALIGNANT MELANOMA -------
CMM tumours are classified into five histologic types: lentigo maligna 
melanoma, superficial spreading melanoma, nodular melanoma, acral­
lentiginous melanoma and desmoplastic melanoma. As the desmoplastic 
variety of tumour is very rare (McGovern & Murad, 1 985), discussion will 
focus on the four most common types of CMM. 
2.3.1 Lentigo Maligna Melanoma 
Lentigo maligna melanoma arises from a noninvasive malignant lesion 
(also known as Hutchinson's freckle). Lentigo maligna develops as a tan or 
brown macule with uneven, superficial black spots on sun-exposed areas of 
the body such as the face (Figure 2.9). Lentigo maligna melanoma occurs with 
an incidence of approximately 7% of CMMs (Davis, 1982, pg. 72). The 
condition is diagnosed most often in the elderly, as lentigo maligna usually 
arises in the fourth decade of life or later; there is a slow, insidious 
development of malignancy over a period of rarely less than 20 years (Davis, 
1982, pg. 72). A notable increase in size, darkening and/or bleeding of a 
lentigo maligna lesion heralds the change from noninvasive to invasive 
growth. 
Figure 2.9. Lentigo maligna melanoma. 
Note the irregular border and dark brown areas which are 
characteristic of the lesions. 
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2.3.2 Superficial Spreading Melanoma 
Superficial spreading melanoma is the most common form of CMM, 
estimated to account for 55-75% of all of CMMs (Davis, 1982, pg. 72). 
Superficial spreading melanoma can be diagnosed at any age; however it 
usually begins in middle age. Although these lesions can occur anywhere on 
the body, they most commonly appear on the lower legs of women and torsos 
of men. Lesions are irregular, raised plaques, multicoloured with white, red, 
blue or black areas and blue-black nodules (Figure 2.10). Horizontal growth 
may continue for several years (as lentigo maligna does for decades) before 
invasive vertical growth into the dermis. 
Figure 2.10. Superficial spreading melanoma. 
The multi-coloured appearance is characteristic of 
the lesion. 
2.3.3 Acral-Lentiginous Melanoma 
Acral-lentiginous melanoma arises on the palmar, plantar and 
subungual tissues, notably the distal phalanges of the fingers and toes (Figure 
2. 1 1 ). It is the least common type of CMM, accounting for approximately 1 % 
of CMMs (Davis, 1 982, pg. 74). Acral-lentiginous melanoma initially 
manifests as an irregular brown or black macule on the sole, palm, digit or 
nail-bed and is often mistaken for a haematoma or fungal infection. 
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Histologically, acral-lentiginous melanoma resembles lentigo maligna 
melanoma and shares a similar lengthy stage of non-invasiveness. Subungual 
acral-lentiginous melanoma cannot be staged using thickness criteria, as 
invasive growth is noted histologically by nail erosion, scaling, furrowing or 
elevation. Eventually the subungual acral-lentiginous melanoma ulcerates to 
push the nail aside. Although acral-lentiginous melanoma is the least common 
of the four types of CMM, it is the most common melanoma of non-white 
persons (Davis, 1982, pg. 7 4). 
Figure 2.11. Acral-lentiginous melanoma. 
Lesions located in the nail-bed of thumb (A) and plantar surfaces (B, C) of the 
foot. 
2.3.4 Nodular Melanoma 
Nodular melanoma (Figure 2.12) is the second most common type of 
CMM (15-30%) with a very high risk of metastasis due to aggressive, invasive 
vertical growth of the nodule (Davis, 1982, pg. 72). An increase in lesion 
pigmentation usually precedes nodular enlargement; eventual ulceration and 
bleeding are late signs of malignancy. Nodular melanoma is histologically 
characterised from other types of CMM by its nodules of large, epithelioid 
melanocytes expanding exclusively in a vertical manner into the dermis 
(Davis, 1982, pg. 72). 
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Figure 2.12. Nodular melanoma. 
2.3.5 Histopathology of CMM 
Transformation of the normal melanocyte to neoplasia leads to a 
relatively uniform progression of cellular pathology. Morphologically, CMMs 
may contain cell types that are epithelioid (rounded) or lentiginous (spindle) 
shaped. Tumours with predominantly epithelioid shaped cells tend to organise 
atypical cells into "nests" whereas tumours with spindle shaped cells organise 
into irregularly branched formations. The histopathological features in the 
early stages of CMM show an accumulation of neoplastic cells in the 
epidermis above the basement membrane; at this stage the lamina may or may 
not be intact, however the tumour is thought to have no metastatic potential 
due to inaccessibility of blood vessels and lymphatics situated below the 
basement membrane. 
As the neoplasm continues to develop, cells penetrate the papillary 
dermis (fingerlike projections of the dermis between the rete ridges of the 
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epidermis) . In the earliest portion of this stage, only single neoplastic cells 
invade the papillary dermis; therefore, the metastatic potential of the lesion is 
still considered to be zero. Following invasion of the papillary dermis, tumour 
cells acquire the ability to proliferate in the cellular and stromal environment 
of the dermis. Proliferating intra-dermal tumour cells aggregate into multi­
celled populations that continue to expand to the level of the reticular dermis. 
At this stage, an initial, slight risk of metastasis exists, gradually increasing as 
the tumour invades deeper into the dermis. Once CMM invades the reticular 
dermis and eventually the subcutaneous fat, the risk of metastasis is great and 
visceral metastases are likely to occur. 
2.3.6 Diagnosis/Staging of CMM 
There are currently two systems employed to grade or stage CMM. The 
Breslow system (Breslow, 197 5) is based on the total thickness of the tumour 
as measured from the outermost layer of the stratum granulosum to the 
deepest point of tumour invasion into the dermis during the vertical growth 
stage. This measurement has a strong predictive value in the prognosis of 
patients with non-metastatic melanomas (Table 2) . The Clark system (Clark et 
al., 197 5) grades a tumour according to depth of invasion of atypical cells or 
inflammatory infiltrates in relation to cutaneous histologic structures and 
correlates prognosis to the anatomic level of involvement (Table 3) . 
Table 2. The Breslow system of tumour grading/prognosis (Breslow, 1975). 
Total thickness of tumour Five Year Survival Rate 
0.00-0. 7 6mm 98-99% 
0.76-1 .49mm 85% 
1 .50-2.49mm 84% 
4.00mm 44% 
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Table 3. The Clark system of tumour grading/prognosis (Clark et al., 1975) . 
Clark System Five Year Survival Rate 
Level I-Tumour is confined to the 100-98°/o 
epidermis and is above the basement 
membrane 
Level II- Invasive cells are present 96-72°/o 
solely in the papillary dermis 
Level III- Tumour cells are seen 90-46°/o 
throughout the papillary dermis with 
impingement on the reticular dermis 
Level IV- Tumour cells are seen 67-31% 
between collagen bundles of the 
reticular dermis 
Level V- Tumour cells are seen m 48-12% 
the subcutaneous fat 
Following diagnosis of CMM, subsequent measures attempt to discern 
whether the cancer remains localised or has metastasised. The presence of 
metastases leads to a particularly unfavorable prognosis for the patient as 
CMM proves resistant to many conventional therapies. CMM progression has 
been the focus of much study and a review of these studies in its entirety 
would be insurmountable; therefore, this review is focused on events of 
progression thought potentially related to PAX3 expression. 
25 
2.4 PAX3/ Pax3EXPRESSI0N-------------
Nine members of the PAX family of genes derive their name from a 
384 hp DNA paired box sequence that encodes a highly conserved DNA 
binding domain termed the paired domain (Burri et al., 1989; Krauss et al., 
1991). PAX genes are further classified into groups (I-IV) according to 
possession of a full or partial homeodomain, another important DNA binding 
domain. (Figure 2.20). The PAXJ gene, located at 2q35 (Ishikiriyama, 1993), 
encodes a class II.I PAX protein transcription factor. 
2.4.1 Pax3 in Embryogenesis 
Pax3 is amongst the earliest transcription factors functioning during 
embryogenesis (Goulding et al., 1991). Within the neural tube, it is expressed 
in cells that specify dorsal neurons (Goulding et al., 1991) and plays a role in 
neural tube closure (Li et al., 1999). 
Pax3 expression is also required for survival and migration of myogenic 
precursor cells. In mice, Pax3 is expressed in early somites as segmentation of 
the paraxial mesoderm occurs (Goulding et al., 1991; Maroto et al., 1997; 
Heanue et al., 1999). Expression in cells of the medial lateral edge of somites 
denotes early stages of myogenic cell specification and cells arising from the 
hypaxial portion of the dermamyotome (medial lateral portion of the somite) 
migrate laterally to enter limb bud regions where they become limb 
musculature (Goulding et al., 1991; Williams & Ordahl, 1994; Tremblay et al., 
1998; Henderson et al., 1999; Lamey et al., 2004). 
Finally, Pax3 functions in specification and migration of neural crest 
derived cells fated to become enteric ganglia (Lang et al., 2000), heart septum 
(Li et al., 1999), Schwann cells (Kioussi et al., 1995) and melanocytes of the 
skin and hair follicles (Galibert et al., 1999). As stated previously, melanoblasts 
are derived from the neural crest where Pax3 is expressed in melanoblast 
precursor cells prior to their migration from the neural crest (Galibert et al., 
26 
1999). PAX3/Pax3 is thought to function in both proliferation of 
melanoblasts (Hornyak et al., 2001) and differentiation of melanocytes through 
regulation of gene expression involved in melanin production (Galibert et al. , 
1999). 
2.4.2 Pax3 Mutations 
The role of Pax3 has been largely determined by studies in Pax3 mutant 
Splotch mice (Figure 2.13). The name 'Splotch' refers to melanocytic defects 
resulting in splotchy pigmentation abnormalities of the fur. Homozygous 
Splotch mice (PaxJ-1) die at embryonic day 1 4  due to neural tube defects in the 
lumbosacral region leading to spina bifida and exencephaly (Fleming & Copp, 
1998; Moase & Trasler, 1992). In a study done in 1999, Splotch mice with 
transgenic Pax3 expression in the neural tube and neural crest demonstrated 
rescue of neural tube closure and these mice did not have exencephaly (Li et 
al., 1999). 
In the Splotch mouse, mutations in Pax3 affect myogenesis due to a 
failure of myoblasts to migrate into the limb buds (Bober et al., 1994; Franz et 
al., 1993). In transgenic mice with inhibited Pax3 expression in the somites, 
pups reveal absence of diaphragm, supraspinatus, infraspinatus, subscapularis, 
terres minor and all distal limb muscles, consistent with the finding that 
hypaxial muscles arise from Pax3+ cells of the lateral somites (Li et al., 1999). 
Mutations in Pax3 also lead to a number of neurocristopathies. Lang et 
al (2000) compared development of Splotch mice to transgenic mice in which 
Pax3 expression was restored to the neural tube and neural crest. Analysis of 
these pups demonstrated that where Pax3 expression was restored, embryos 
showed enteric ganglion formation. Furthermore, Splotch mice have cardiac 
defects due to failure of septation in the truncus arteriosus (Epstein et al., 
1996; Franz et al., 1989). Li et al. (1999) demonstrated that transgenic Splotch 
mice with re-expression of Pax3 in the neural crest restored cardiac flow 
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septation and promoted survival until birth. 
Finally, Pax3 mutations result in hearing, craniofacial and pigmentation 
anomalies which demonstrate variability in penetrance and expressivity. 
Asher et al. (1996) stated that a minimum of two genes, one of these being 
either X-linked or sex-influenced and the other autosomal, interact with the 
Splotch Pax3 mutation to influence the craniofacial features of Splotch mice and 
concluded that further studies may lead to identification of genes that interact 
in order to modify the expression of human PAX3 mutations in Waardenburg 
syndrome. 
Figure 2.13. Photomicrograph of a Splotch Murine Embryo. 
The mouse embryo on the left is a Pax3 mutant "Splotch" mouse. Note the 
defects in the area of the neural tube, neural crest derived cranial facial structures 
and limb bud formation as compared to the wild type mouse on the right. 
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2.4.3 PAXJMutations 
Mutations in human PAX3 are associated with Waardenburg syndrome 
Type 1 ,  an autosomal dominant condition that presents with deafness ana 
pigmentary disturbances due to dysfunction in the proliferation of neural crest 
derived cells (Tassabehji et al. , 1 993) .  Mutations in PAX3 encode abnormal 
transcription factors that are unable to regulate transcription of 
micropthalmia-associated transcription factor (MITF). MITF functions ill 
survival of melanoblasts and synthesis of enzymes involved in melanogenesis; 
therefore, loss of MITF results in the absence of functioning melanocytes in 
the stria vascularis and hair follicles (Figure 2. 1 4) (Bentley et al., 1 994; Ganss et 
al. , 1 994; Yasumoto et a/., 1 994; Tachibana et a/., 1 996) .  
Figure 2.14. Children affected by 
Waardenburg Syndrome I.  
The white forelock is a pigmentation 
defect in the hair follicles due to absence of 
melanocytes. 
It can be seen from mutation studies that P AX3 / Pax3 plays an 
important role in the early development of particular lineages, most likely 
being associated with cellular proliferation, migration and/ or regulation of the 
migratory phenotype of Pax3 expressing cells. In CMM, P AX3 mutations do 
not occur; rather, aberrant expression of a particular isoform is demonstrated. 
Knowing this led to the hypothesis that the developmental role of P AX3 may 
be re-activated in CMM and thus contribute to neoplastic progression. 
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2.4.4 Alternative PAX3Transcripts 
Functional diversity of P AX3 / Fax3 in vivo is linked to its ability to 
produce alternatively spliced gene products which alter the structure and 
consequently the binding activity of the paired and homeodomain regions 
(fsukamoto et al., 1994; Underhill & Gros, 1997; Seo et al., 1998). Originally 
FAX3 was thought to contain only eight exons. Recent studies show that 
P AX3 / Fax3 may be alternately spliced at exons 4, 5, 8, and 9 to produce 
many different transcripts including transcripts that lack an entire homeobox 
(Parker et al., 2004; Pritchard et aL, 2003; Barber et al., 1999; Tsukamoto et al., 
1994) (Figure 2.15). 
Pax3a 
Pax3b 
Pax3c 10 
Pax3d 
Pax3e 
Pax3f 
Figure 2.15. Alternate transcripts of P.AX1produced by alternate splicing. 
An arrow for each transcript indicates the predicted locations of translation 
termination. Pax3a and Pax3b) These transcripts lack the entire homeobox and 3' end 
(Tsukamoto et al., 1994). Pax3c) Transcript containing 8 exons and a stop codon 5 hp 
into intron 8 (Goulding et al. , 1991). Pax3d) Transcript contains exon 9 spliced directly 
onto 3' end of exon 8 (Barber et al., 1999). Paxe) transcript containing 10 exons Barber 
et al., 1999). Pax3f) transcript found in murine cDNA that contains exon 9 directly 
spliced to the 3' end of exon 5 Barber et al., 1999). 
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Alternate transcripts are likely to encode proteins with different binding 
and transactivation activities therefore having an important effect on the 
functional role of the gene (Underhill & Gros, 1997; Fortin et al., 1998) 
Generation of differing transcripts of PAX3/Pax3 is accomplished by post­
transcriptional pre-mRNA splicing and central to this research was the 
identification and analysis of constitutive and cryptic splice sites that generate 
alternate P AXJ / Pax} transcripts found expressed in various tissues. 
Therefore, an intricate understanding of splice site consensus sequences, 
splice site selection and splicing machinery involved in pre-mRNA processing 
was essential to understand the observed P AXJ / Pax} transcript expression 
profiles in CMM, murine embryogenesis and specifically melanogenesis. 
2.4.5 Generation of Alternate PAX3Transcripts 
RNA splicing is dependent on the existence of consensus sequences 
located at exon/intron boundaries and within the intron itself. Small nuclear 
ribonucleoproteins (snurps) and splicing factors bind to consensus sequences 
leading to assembly of the splicing machinery (sliceosome). Briefly, base 
pairing of the U1 snurp occurs at the 5' splice site consensus sequence 
GUA/GU located at the exon/intron border and this signals subsequent 
events (Mount et a!., 1983; Black et a!., 1985; Watakabe et a!., 1992). The U2 
snurp then binds to the branchpoint sequence CTA/GAC/T within the 
intron causing the adenosine residue to bulge out, forming a lariat structure 
(Pikielny et al., 1986; Cheng & Abelson, 1987; Konarski & Sharp, 1987;  
Zhuang et al., 1989). Further splicing factors bind to a polypyrimidine tract 
(PPT) located within the intron (Green et al., 1991). Finally, snurps U4, US 
and U6 bind to the 3' consensus sequence YAG (Y is a pyrimidine) located at 
the intron/exon border (Pikielny et al., 1986; Konarski & Sharp, 1987; Cheng 
& Abelson, 1987) (Figure 2.16A). 
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Figure 2.16 Initial pre-mRNA splicing. 
A.) Assembly of the spliceosome. Exons denoted by boxes, intron indicated as a 
solid line; consensus sequences are letters along line; snurps and splicing factors are 
coloured circles. 
B.) Step one of intron excision. Assembly of the spliceosome causes 
conformational change of the gene such that the 2' OH of the bulged out branchpoint 
adenosine is able to disrupt the phosphodiester bond (P in circle) at the 5' splice site (blue 
arrow indicates disruption of phosphodiester bond) 
The excision process occurs in two steps. Step one occurs as assembly 
of the spliceosome causes conformational change of the pre-mRNA such that 
the 2' OH of the branchpoint adenosine is able to disrupt the phosphodiester 
bond at the 5' splice site, releasing the upstream exon and forming the lariat 
intron intermediate (Figure 2.1 6B) . Step two proceeds as the hydroxyl group 
of the cleaved upstream exon attacks the phosphodiester bond at the 3' splice 
site (Figure 2 .1 6C) resulting in displacement of the lariat intron and ligation of 
the two exons (Figure 2 .1 6D) . 
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Figure 2.16 (cont). Final pre-mRNA Splicing. 
C.) Diagram depicting release of upstream exon (red box), formation of lariat 
intron (loop on left) , and disruption of 3' phosphodiester bond (P in circle) ; blue arrow 
indicates proximity of OH of cleaved upstream exon to 3' bond. Step two proceeds as the 
hydroxyl group of the cleaved upstream exon attacks the phosphodiester bond at the 3' 
splice site resulting in displacement of the lariat intron and ligation of the two exons. 
D.) Diagram depicting release of lariat intron (on left) and ligation of exons 
(coloured boxes) . 
Normally, RNA processing guarantees that the 5' donor site· pairs with 
the closest 3' acceptor site. Many genes, such as P AXJ, however, have 
sequences which are ambiguous, therefore the spliceosome may search for 
additional splice site choices up or downstream from ambiguous sequences. 
The function of gene splice site selection is thought linked to production of 
tissue specific transcripts, although mechanisms for splice site selection are 
presently unknown. 
2.4.6 PAX3Cand PAX3DTranscripts 
PAXJC mRNA is transcribed from exons 1 -8. The sequence for the 3' 
end (beginning at exon 8) is shown below and is generated using the stop 
codon and polyadenylation signals located within intron 8 (Figure 2. 1 7) .  
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AGGTAATGGG ACTCCTGACC AACCACGGTG GGGTACCTCA TCAGCCCCAG ACTGATTACG 
CGCTCTCCCC TCTCACCGGG GGTCTGGAAC CTACCACCAC GGTGTCGGCC AGCTGCAGTC 
AGAGACTAGA CCATATGAAG AGCTTGGACA GTCTGCCAAC ATCTCAGTCC TACTGTCCAC 
CCACCTATAG CACCACAGGC TACAGTATGG ACCCTGTCAC AGGCTACCAA TATGGGCAGT 
ATGGACAAAg taagccttgg actttttagg gggcaatttc tcctggaagg gagataaact 
caactcttcc ttaagaaagg tgaattagag gcaagattaa gccacacatg ccggtatcaa 
tttttttttt tgcaaagcca gctgactgtt ccagcagggg cttccttgtg taattatttt 
cttaactgat gtcaacaaca tcttgcggtt attaattgtt gagacgtgaa acctgattgc 
cactaggtaa aacacaaggg ttggccaaaa tgaaataatc cctgacatta gaaacacatg 
ttcttaatga ggtcagctcc aggatcatat gggggataat cccagggaca caaagttgtg 
tcaaacttgt ctcaggaata aaaatattag tctcaagcct ttgatagcac ggtattaaat 
atgacattgt cagcctgtag ctgatcttgc ccctgactgt gaattgtccc agcatgacct 
aaaaagctgc gtgtgtttcc cagGTGC CTTTCATTAT CTCAAGCCAG ATATCGCGTA 
AGTGAACTGT CCACTTGGAG CTAAAACTGG CCCTGTTTCT GGTCTTCGCA GCCTAGATAT 
GAAGAATCTG CTCTGAAAAC AAAAAAAAAT TACCCTITTG TTGGGGGGGG TGGGGCAGTG 
GTCCCAATAG GAGACAAAGG AGAGTGATTG ATITICTTCC TCCAATAGTT GGTTTCAAAT 
CCTITTGAAC ACGTTCGACA AAAGCAGTGG AGAAGAGGAA GACCTGGAGC AATAAA 
Figure 2.17. Differing generation of the PAX3C and PAX3D transcripts. 
Shown is the genomic sequence of P AX3, from exon 8. Exons 8 and 9 are denoted by 
large case letters while the intronic region is denoted by small case. In generation of the 
PAX3C pre-mRNA, splicing machinery recognises a signal for cleavage and adenylation 
located within the intronic region (indicated in red) . In generation of the PAX3D pre-mRNA 
transcript, splicing machinery ignores the first signal for cleavage and polyadenylation used for 
P AX3C (in red) and continues transcription until the signal for cleavage and adenylation at the 
sequences indicated by pink lettering. This longer pre-mRNA will then be spliced at S' and 3' 
consensus donor/ acceptor sites (indicated in blue) utilising the branchpoint sequence and 
polypyrimidine tract indicated by green and orange lettering, respectively. 
PAXJD mRNA is transcribed from exons 1-9 and has been found 
highly expressed in CMM, yet not expressed in normal skin (Barr et al. , 1 999; 
Scholl et al. , 2000). The donor site for intron 8 is located 11 nucleotides 
upstream of the P AXJC stop codon with intron 8 branchpoint, 
polypyrimidine tract and acceptor site located downstream. In generation of 
the P AX3 D transcript, splicing machinery ignores the first signal for cleavage 
and polyadenylation used for PAXJC and instead continues transcription 
producing a longer pre-mRNA that will be spliced at alternative 
donor/ acceptor sites. It is interesting to note that the P AXJD splice sites are 
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Analysis of the generation of varying P AX3 /Pax3 isoforms was a focal 
point of this study as the predominant isoform expressed in CMM is the 
PAX3D isoform (Barr et aL, 1999). This being the case, it was thought curious 
that mRNA transcription in CMM utilises the weaker splice elements 
continuously over the constitutive splice sites. Therefore, the expression of 
Pax3d has been examined during stages of murine embryogenesis and 
melanogenesis to understand its possible significance in CMM. 
2.4. 7 PAX3 and CMM 
Results from previous studies have raised the possibility that P AX3 
regulated developmental programs may be at work in CMM cells and that 
neoplastic melanocytic cells may be functioning in a manner similar to 
pluripotent embryonic neural crest cells. The first indication that P AX3 
regulated developmental programs may be involved in the progression of 
CMM is the strong expression of P AX3 in CMM cells, whereas little or no 
expression is observed in normal adult melanocytes (Scholl et aL, 2001). 
Although mutations in PAX genes are associated with many forms of cancer 
(Bennicelli et al., 1996; Iida et al., 1996; Kroll et al., 2000), this is not the case in 
CMM, where causative mutations are at gene loci other than those of the 
PAX gene family. However, of note is the increased expression and aberrant 
expression profile of P AX3 transcripts in CMM. 
Aberrant expression of P AX3 in CMM was first detected by Barr et al. 
(1999), who reasoned that expression of PAX genes in neural crest 
progenitors might be repeated in tumour cells arising from the same lineage. 
Using RNAse protection assays to quantify PAX3 expression in both cell 
lines and tumour tissue from CMM, they found that levels of P AX3 were 
"notably high". They also observed the predominant transcript found 
expressed in CMM was the PAX3D transcript, although PAX3C is also 
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expressed. These findings raised the possibility that the phenotype of CMM 
may be related to increased aberrant expression of PAX3D. 
No published studies (to date) have identified expression of 
PAX3D/Pax3d or their encoded proteins in normal melanocytic tissues; 
therefore, it is not yet known whether this protein has a particular role in 
transcriptional regulation of the melanoblast. Differences in the structure of 
the C-terminal region of PAX3/Pax3 isoforms influence protein-protein 
interactions of transactivational domains and thus transcriptional activation of 
downstream targets bound by P AX3 /Pax3 via its paired DNA binding 
domain. Therefore, a primary aim of this research was to investigate 
PAX3C/PAX3D and Pax3c/Pax3d expression profiles in CMM and murine 
tissues hoping to gain insight into a possible role for PAX3C/Pax3c and 
P AX3D /Pax3d proteins. 
2.4.8 PAX3 Mediated Transcriptional Activation 
Transcription factors such as P AX3 /Pax3 reqwre two functional 
domains within their protein structure to assist in transcription of target genes 
into RNA. Firstly, a DNA binding domain must recognise and bind specific 
regulatory sequences within promotor/ enhancer regions of the target gene 
DNA; secondly, the transactivating domain of the transcription factor protein 
associates with basal transcriptional machinery and influences gene 
expression. Furthermore, the transactivation domain functions to recruit 
components of the pre-initiation complex, other transcription factors or 
transcriptional machinery to the area of the gene promotor, facilitating the 
formation of the protein-DNA complex which signals RNA polymerase to 
begin initiation and transcription of the gene (Ptashne, 1988; Mitchell & Tijan, 
1989). The P AX3C/P AX3D and Pax3c/Pax3d isoforms analysed in this study 
vary only in the length and composition of their transactivation domains. The 
alternate C' end may confer different transcriptional ability to PAX3 binding 
domains or they may be associated with varying DNA target selection. 
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2.4.9 PAX3 DNA Binding Domains 
P AX3 /Pax3 has two DNA binding domains within its structure, a 
paired domain (PD) and a paired type homeodomain (HD) (Figure 2.20). 
PO 
HD 
TD 
Figure 2.20. Molecular structure of the Pax3 protein. 
Pax3 protein contains a paired domain (PD) 
consisting of PAI (N) and RED(C) subdomains, each of 
which is composed of three helices in a helix-tum-helix 
motif. The third helix of each subdomain is shown in 
contact with the target DNA. The Pax3 protein also 
contains an octapeptide (OP) followed by a 
homeodomain (HD) containing an additional helix-turn­
helix DNA binding domain. Finally, the transactivation 
domain (TD) is indicated. 
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Structural analysis has revealed that the PD consists of two 
independent helix-tum-helix subdomains, an N-terminal (PAI) and a C­
terminal (RED) (Xu et al, 1995) . Mutations in the PAI subdomain result in a 
loss of both PD and HD binding (Underhill et al, 1995; Fortin et al, 1997; 
Underhill & Gros, 1997) perhaps due to loss of crucial major and minor 
groove DNA contacts (Xu et al, 1995) . The RED subdomain has been shown 
to be dispensable for binding in deletion studies (Wilson et al, 1993; 
Miskiewicz et al, 1996) ; however, more recent studies detailing distinct PD C­
terminal subdomain sequence preferences amongst Pax family members 
suggests that this subdomain may be used for discrimination of DNA targets 
(\! ogan & Gros, 1997) . 
The 61 amino acid HD conforms to a helix-tum-helix motif (Wilson et 
al, 1995) and is able to bind DNA both monomerically recognising an ATTA 
motif and as a dimer utilising a palindromic motif of 5' TAAT(N)2_3ATTA 3' 
(Wilson et al, 1993) . It is suggested that binding of the initial HD cause DNA 
distortions thus preparing a template for further binding by the second HD. 
Because the binding affinity of the HD as a monomer is considered weak, 
homodimerisation of the HD is thought to enable recognition of target 
sequences long enough to ensure further binding specificity and affinity 
(Wilson et al, 1995) . 
Alone, the 128 amino acid PD recognises a GTCAC binding motif 
(Epstein et al, 1993; Chalepakis & Gross, 1995) . However, when binding in 
conjunction with the homeodomain, the paired domain recognises either a 
GTTCC motif (Chalepakis et al, 1994) or a GTTAT motif (Phelan & Loeken, 
1998) located downstream of the consensus homeodomain motif of ATTA. 
Paired and homeo- DNA binding domains have been seen expressed 
separately in Caenorhabditis elegans, suggesting functional independence 
(Chisholm & Horvitz, 1995; Zhang & Emmons, 1995) . However, mutations 
of the PD in the human PAX3 protein such as those seen in Waardenburg 
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syndrome have been shown to affect or abrogate DNA binding by the HD, 
signifying that the two domains function interdependently (Baldwin et al., 
1995; Fortin et al., 1997). Moreover, in vitro binding studies have illustrated 
cooperative interactions between the PD and the HD of P AX3 Qun & 
Desplan, 1996; Vogan & Gros, 1997; Underhill & Gros, 1997; Fortin & Gros, 
1998). 
To further illustrate the complexity involved in PAX3 target gene 
selection and binding, recent studies have demonstrated that PAX3 interacts 
with other factors to activate promotor and enhancer regions of downstream 
target genes. For example, Sox10 and Pax3 synergise to activate the c-RET 
gene enhancer (Lang et al., 2000). Pax3 and Sox10 physically interact with each 
other through contacts mediated by the PD while at the same time Pax3 binds 
the c-RET enhancer via a PD-DNA protein interaction (Lang & Epstein, 
2003). In contrast, SOX10 and PAX3 must bind DNA recognition elements 
independently in order to synergistically upregulate the MITF gene promotor 
(Bondurand et al., 2000). In this interaction, PAX3 binds DNA utilising the 
HD (Lang & Epstein, 2003). In summary, it is notable that PAX3 interacts 
with the c-RET enhancer via PD-DNA interactions, while it binds the MITF 
promotor via HD-DNA interactions. This illustrates how alternate 
P AX3 /Pax3 proteins may play different roles to activate different 
downstream gene targets during development and CMM. 
2.4.10 P AX3 Trans activation Domains 
It is now generally accepted that transcription factors function through 
the transactivating region of the protein by interaction with proteins of the 
basal transcriptional machinery including RNA polymerase II (Ptashe & 
Gann, 2002). There is strong evidence that the mechanism by which trans­
activators function is via "recruitment". The recruitment model of 
transcriptional activation states that the trans-activation regions of the 
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transcription factor serve to attract the basal transcription complex to the 
vicinity of the promotor region of the gene leading to a signal for polymerase 
II to initiate transcription (Barberis et al., 1995; Gaudreau et al., 1998; 
Keaveney & Struhl, 1998). 
The transactivation domain of P AX3 /Pax3 is located within the last 78 
COOH-terminal amino acids and is classified as a praline-serine-threonine 
(PS1) activation domain due to the amino acid composition (Chalepakis et al., 
1993). COOH-terminal deletion studies of PAX3/Pax3 further support the 
recruitment model; these studies have shown that deletion of part or the 
entire COOH transactivation domain of PAX3/Pax3 results in the failure of 
mutant proteins to tran-sactivate reporter genes (Chalepakis et al., 1994; 
Bondurand et al., 2000; Cao & Wang, 2000; Pritchard et al., 2002). Similar 
results were obtained in a study in which the transcriptional competence of 
Pax2, PaxS and Pax8 were eliminated via a frameshift mutation in the 
transactivating region of the protein (Dorfler & Busslinger, 1996). 
2.4.11 P AX3 and the Basal Transcriptional Complex 
To date there are no studies demonstrating a direct interaction between 
the transactivating region of PAX3/Pax3 and the basal transcriptional 
complex. However, Smit et al (2000) demonstrated an interaction of Pax3, 
Sox10 and Bm-2 cofactors with TATA-box-binding protein and p300, two 
components of the basal transcriptional complex. Cvekl et al (1999) also 
demonstrated protein-protein interactions of the C-terminal-activation 
domain of Pax6 with the TATA-binding-protein. 
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2.5 MELANOCYTIC SURVIVAL FACTORS --------
Since P AXJ is over-expressed in CMM, an investigation of possible 
candidate downstream target genes was undertaken. Review of key 
developmental genes involved in melanogenetic events as well as evidence 
suggesting c-KI.T and MJTF may be probable cofactors or downstream targets 
of P AXJ in melanoblast proliferation, migration or differentiation prompted 
further investigation of their co-expression in this study. 
2.5.1 The c-K/TGene 
The c-KI.T gene encodes a receptor tyrosine kinase which, along with its 
ligand, stem cell factor (SCP), has been shown to play a crucial role in the 
survival and migration of melanoblasts. Expression patterns of SCF have 
suggested that c-Kit/SCF mediates migratory or chemotactic processes for c­
Kit expressing cells. 
In the embryo, neural crest cells initially produce SCF, which functions 
in an autocrine fashion to induce melanogenesis in adjacent c-Kit expressing 
crest cells. Werhle-Haller & Weston (1995) demonstrated soluble SCF 
functions to disperse c-Kil melanoblasts along a dorsolateral pathway, 
whereas membrane bound SCF induces migration from the neural crest to the 
dermis. Subsequently, SCF is expressed in the mesenchyme of embryonic skin 
during the period in which c-Kil melanoblasts migrate from the neural crest 
toward the dermis (Matsui et al., 1990; Manova & Bachvarova, 1991; Werle­
haller & Weston, 199 5). 
Nishikawa et al (1991) and Yoshida et al (1996) demonstrated that stages 
of melanoblast migration and proliferation require c-Kit expression. 
Specifically, entry into and proliferation within the epidermis is dependent 
upon c-Kit expression; this is in contrast to a period just prior to epidermal 
invasion, when melanoblasts are dormant in the dermis and c-Kit negative. 
SCF / c-Kit signalling is also required in the development of the hair 
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follicle pigmentary unit. Before the onset of hair follicle morphogenesis, in 
perinatal mice, c-Kit expressing melanoblasts are seen migrating into the 
developing hair placode where widespread epithelial SCF expression exists 
(Peters et al., 2002). Thus it is apparent that c-Kit expression plays an 
important role in the temporal regulation of melanoblast proliferation and 
migration. 
2.5.2 Alterations of c-Kit Signaling Pathways 
Murine transgenic studies and mutational analyses of c-Kit have shown 
that this gene is crucial for melanocyte development since this gene affects the 
functional role of the encoded tyrosine receptor (Nishikawa, 1991; Galli et al., 
1993; Grab be et al., 1994; Broudy, 1997). In humans, mutations in c-KIT result 
in piebaldism, a syndrome in which affected individuals possess a white 
forelock and absence of pigmentation of the medial portion of the forehead, 
eyebrows and chin, chest, abdomen, and extremities. This mutation in c-KIT 
leads to substitution of leucine for phenylalanine at codon 584 within the 
tyrosine kinase domain of the c-KIT receptor (Giebel & Spritz, 1991). 
2.5.3 c-K/Tand CMM 
Progression of CMM has been correlated to a loss of c-KIT gene 
expression. Increasing loss of the c-KIT receptor has been demonstrated 
during the invasive and metastatic phases of CMM and a majority of CMM 
cell lines lack detectable levels of c-KIT expression (Lassam et al., 1992; Natali 
et al., 1992; Zakut et al., 1993). In a study by Huang et al (1996) transfection of 
the c-Kit gene into c-Kit negative CMM cells was shown to inhibit tumour 
growth and metastasis in nude mice. 
There are several grounds to investigate influence of P AXJ on c-KIT 
expression, the most notable being that the promotor region of the c-KIT gene 
possesses several potential DNA binding sites for the paired and 
43 
homeodomain regions of P AX3 (Figure 2.21 ). No investigation of Pax3 
interactions with c-Kit have been undertaken (to date) to discern repercussions 
of aberrant Pax3d expression on c-Kit expression in CMM. 
1 gagggatgtcttattagtttatcagaatgcatagggaaagctcatctttcttggagtagg 
61  tcttccaataagtgttcaagccctgggtcttccctcactacaataataaacatacctgct 
1 2 1  ctaccctcctcacaaagctgttatcgtgagcatgaaaagacgagtcgctgtggggaagaa 
1 8 1  ctattaacccctatacagatactgttgttgctttccgttcaagga tccaccatgagactg 
241 tgggtaaggcactttctgggcagtgaaatcgggcttaagagaatcattgtacttttattt 
301 tgctcctgggaccggcaagggcagttaagagccctagccctaaaactgtcgtctgttaca 
361 gaggcagagaaatcattactggggttggcagcgttggggggaggggggaaaacgtgtatg 
421 aaaacctgggctcccagagcaaacttcgccacgcgccctccatcgcccctgtctccacac 
481 aagtcccggcaggggcttcttgggcggaggccacgccgaccaataggaacccactgtgtt 
541 cctacaggttacgaagcaggtggagaaattgagcagaaacaattagcgaaaccgggctca 
601 gcctttaccgcggtgccaggagctcctaacaggcctggaggggaatgtcggggctcaatt 
661 tcctaacgctcccctccccatccccatgccacctccacgagcagcggcgtccagcctcct 
721 cccgcccgaacgtgctcgaggggcgggcagtcgacctttattgtctggggagcacctggc 
781 aggtggcgggcccgtgccctaacgtgtgcgtggtgcccagcttcacaaagcgagcgggca 
841 gcacctccttggtccgggaacgcctcagcctggccgtccacatcccaggggtggaaaggt 
901 ggagagagaaaggggctccggagtcaagagcggggagagagggcgcgcgccctcctcctc 
961 ccggcgggcacagccccccggcattaacacgtcgaaagagcaggggccagacgccgccgg 
1021 gaagaagcgagacccgggcgggcgcgagggaggggaggcgaggaggggcgtggccggcgc 
1 081 gcagagggagggcgctgggaggaggggctgctgctcgccgctcgcggctctgggggctcg 
1 1 41 gctttgccgcgctcgctgcacttgggcgagagctggaacgtggaccagagctcggatccc 
1201 atcgcagctaccgcgatgagaggcgctcgcggcgcctgggattttctctgcgttctgctc 
1 261 ctactgcttcgcgtccagacaggtgggacacgcggctggcaccccg 
Figure 2.21. Promotor region of c-KIT. 
Potential P AX3 binding motifs indicated in red. 
Potential P AX3 binding sites, as well as lack of previous co-expression 
studies, overlapping temporal expression in embryogenesis and similarity of 
functional roles in melanocytic development prompted investigation into 
possible co-relations between c-Kit and Pax3 expression in this study. 
Furthermore, c-Kit expression is downregulated in CMM (Huang et aL, 1 996 
and 1 998) while Pax3 is a known gene repressor (Chalepakis et aL, 1 994). 
Therefore, we hypothesised that overexpression of P AX3 in CMM may 
inhibit c-KIT expression, therefore a negative correlation between these genes 
was assessed in melanogenesis. 
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2.5.4 The MITFGene 
Micropthalmia-associated transcription factor (MITF) is a basic helix­
loop-helix transcription factor known to function both in the early survival of 
melanoblasts (Homyak et al., 2001) and subsequently in regulation of genes 
required for synthesis of enzymes involved in melanogenesis (Bentley et al., 
1994; Ganss et al. , 1994; Yasumoto et al., 1994; Tachibana et al., 1996) . 
Furthermore, MITF regulates expression of a melanocortin-1 receptor, a 
receptor involved in determining relative proportions of pheomelanin and 
eumelanin production (Aoki & Moro, 2002) . 
MI1F expression is one of the earliest markers of melanocyte 
differentiation and crucial for melanoblast survival during migration from the 
neural crest (Opdecamp et al., 1997). Studies of strict temporal regulation of 
MITF activity and expression levels during melanocytic development suggest 
that MI1F expression cooperates with many factors working coordinately to 
regulate differentiation of the neural crest cell through melanoblast stages on 
through further differentiation until capable of melanin production (Beerman 
et al., 1992; Ferguuson & Kidson, 1997; Nakayama et al., 1997; Opdecamp et 
al., 1997) . 
2.5.5 MITFMutations 
Mutations in the MI1F gene result in Waardenburg Syndrome type Ila 
(Tassabehji et a! , 1994) , Tietz Syndrome (a hypopigmentation albinism with 
sensorineural deafness) (Smith et al., 2000) or ocular albinism with 
sensorineural deafness (Morell et al., 1997) . Phenotypes of persons in these 
affected families reveal severe congenital sensorineural hearing loss, 
hypopigmentation of follicular melanocytes causing blonde hair to tum grey 
during adolescence, pale skin with numerous orange freckles and blue eyes 
lacking retinal pigmentation. Similarly, in mice, mutations in Miif lead to loss 
of pigmentation in the eye, inner ear, and skin, and to reduced eye size and 
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early-onset deafness (Hodgkinson et al., 1993; Nakayama et al., 1998). 
MITF, like PAX3, produces alternate isoforms which are constitutively 
expressed in various tissues. The neural crest-derived melanocyte specific 
isoform is MITF-M (Y ajima et al., 1999), the predominant isoform in heart 
and kidney is MITF-H (Steingrimsson et al., 1994) and in retinal pigmented 
epithelial cells it is MITF-A (Amae et al., 1998). Both the antibodies used for 
immunohistochemical staining and primers designed to amplify RT-PCR 
products in this study were specific for the melanocyte-specific isoform of 
protein or transcript, respectively. 
2.5.6 MITFand PAX1 
Pax3 has been shown to bind to the promoter and transactivate the 
Mitfm gene (Watanabe et al., 1998). As stated previously, Pax3, along with 
Sox10 have been implicated as having important synergistic effects on 
upregulation of Mitfm expression levels (Bondurand et al., 2000; Potter£ et al, 
2000). Mutations in PAX3 result in generation of protein transcription factors 
unable to regulate transcription of MITF-M; the phenotype of Waardenburg 
Syndrome type I, characterised by pigmentary disorders and hearing loss, 
reflects this. Similarly, Splotch mice bearing Pax3 mutations (leading to a 
nonfunctional Pax3 protein unable to bind to Mitfm) demonstrates the 
dependence of Mitfm on functional Pax3 transcription factors for normal 
expression. The activation of Miifby Pax3 initiates a cascade of genes within a 
genetic hierarchy that brings about differentiation of the melanocytic cell. 
2.5.7 MITFand c-KIT 
There is some controversy over the rank of both c-KIT and MITF in the 
genetic hierarchy of melanocytic specific genes. Evidence supports a feedback 
loop in which MITF regulates c-KIT expression/ activity and c-KIT signaling 
regulates MITF expression/ activity. The c-KIT promoter contains an E-box 
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motif for MITF binding and in vitro analysis has shown that MITF is able to 
activate c-KI.T transcription in cultured cells (Tsujimura et al., 1996). Moreover, 
Opdecamp (1997) has demonstrated that MITF is required for upregulation 
of c-KI.T expression. 
Further studies confirm a feedback loop since c-KIT signaling increases 
MITF phosphorylation leading to stimulation of MITF transcriptional activity 
(Hemesath et al., 1998; Price et al., 1998; Wu et al., 2000; Xu et al., 2000). 
Finally, mice doubly heterozygous for mutations in both c-FJt and Miifhave a 
more severe phenotype than mice heterozygous for either mutation alone 
(Beechey & Harrison, 1994). These and previously mentioned studies suggest 
an interesting interplay between Pax3, c-FJt and Miif expression and 
experiments in this study aim to confirm whether co-relations in their gene 
expression do exist in murine embryogenesis and melanogenesis. 
2.6 CONCLUSION OF LITERATURE REVIE"W-' -------
It is not unlikely that developmental genetic programs regulating cell 
properties may be reactivated in the neoplastic cell. The ability of the 
melanoblast to migrate, proliferate and differentiate is vital, whether in 
embryogenesis or postnatal re-pigmentation processes. We hypothesise that 
the particular properties of the melanoblastic cell that enable it to undergo 
these events in both embryonic and postnatal tissue may be conferred through 
expression of P AXJ, a gene strongly associated with development of 
melanocytic precursor cells. Thus the high, aberrant expression levels of 
PAXJ, consistently observed in CMM, may be directly linked to the 
progression of CMM. 
Clinical research and animal studies have shown that tumourigenesis is 
an event reflecting the properties of both host tissues and the neoplastic cell 
itself. The ability of a cancer cell to take advantage of genetic programs set in 
place specifically for normal cellular events such as cell proliferation, 
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migration and signaling could give the neoplastic cell a tremendous selective 
advantage and therefore enhance both its chance of survival and its ability to 
evade body defenses. In this study, experimentation sought to provide 
information regarding a possible role for P AX3 in the tumourigenesis of 
CMM, in light of important genetic events its encoded transcription factors 
regulate during normal melanocyte development. 
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3 
HYPOTHESES 
& RESEARCH AIMS 
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3.1 HYPOTHESES----------------
• The P AXJ D transcription factor (predominantly expressed in CMM) is 
not a cryptic splice form, but rather, is utilised during the development 
of normal melanocytes. 
• Aberrant expression of PAXJD contributes to the progression of 
CMM through transactivation of MITF-M and/ or repression of c-KI.T 
genes. 
3.2 RESEARCH AIM.._,__ ______________ _ 
• Compare relative mRNA expression of PAXJC/PAXJD in cutaneous 
melanoma biopsies using mRNA isolation, RT-PCR and nucleic acid 
sequencmg. 
• Investigate and compare relative mRNA expression of Pax3c/ Pax3d at 
key stages of murine embryonic development using mRNA isolation, 
R T-PCR and nucleic acid sequencing. 
• Investigate and compare relative mRNA expression of Pax3c/Pax3d in 
an in vivo model of murine melanogenesis using mRNA isolation, RT­
PCR and nucleic acid sequencing. 
• Assess spatial and temporal Pax3c/Pax3d protein expression m 
developing murine embryos at key stages of melanocytic development 
by immunohistochemistry. 
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4 
METHODS 
5 1  
4.1 PAX3TRANSCRIPT ANALYSIS IN CMM 
4.1.1 Human Tissue Collection 
Five metastatic CMM excised from regional lymph nodes were acquired 
through Clinical Professor Dominic Spagnolo of PathCentre (Perth, WA). 
Following patient consent, samples were snap-frozen in liquid nitrogen 
immediately following surgical excision and stored at -70° until use, according 
to PathCentre protocol for acquisition and storage of tissue samples for 
research use. Subsequent collaboration with surgeons allowed samples to be 
retrieved from tissue archives; ethical clearance for use of the human tissues 
was acquired through the Human Ethics Committee of Edith Cowan 
University (project #02-68). 
4.1.2 Isolation of Total RNA 
Total RNA was isolated from samples usmg TriZol Reagent 
(Invitrogen). Tissues were homogenised in lmL of TriZol per 50-100 mg of 
tissue using a glass-col homogeniser. Homogenised samples were incubated at 
15°-30° for 5 minutes. 0.2mL of chloroform was added followed by 3 minutes 
incubation at 15°-30°. Samples were centrifuged at 12000rpm for 15 minutes 
at 2° -8° to isolate the RNA into the aqueous phase of the solution. RNA was 
precipitated from the aqueous phase by addition of 0.5 mL of isopropyl 
alcohol, incubation for 10 minutes at 15°-30° and centrifuged at 12000rpm at 
2° -8° for 10 minutes. RNA precipitates were washed with 1 mL 7 5% ethanol, 
centrifuged at 7500rpm at 2°-8° for 5 minutes and briefly air-dried for 10 
minutes. RNA was redissolved in 0.4 mL RNase free water and incubated at 
60° for 10 minutes. Integrity of the total RNA extracted from the samples was 
assessed by 1 % agarose-gel electrophoresis and ethidium bromide stained 
visualisation of the gel under UV light.. 
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4.1.3 PolyA+ mRNA Purification 
An Oligotex mRNA kit (Qiagen) was utilised according to the 
manufacturer's instructions. Briefly, mRNA, containing polyadenylated tails 
was isolated from total RNA by hybridisation of the poly A+ tail to a dT 
oligomer coupled to a solid-phase matrix. Following separation of the 
mRNA:Oligotex complex, poly A+ mRNA was eluted from the matrix using 
120µL SmM Tris-Cl (pH 7.5) and stored at -70°C until further use. 
4.1.4 RT-PCR Analysis of PAX3C/PAX3llfranscripts 
Negative controls for each polyA + sample were performed by 
elimination of the reverse transcription portion of reverse transcription­
polymerase chain reaction (RT-PCR) . RT-PCR products were assessed by 2% 
agarose-gel electrophoresis and ethidium bromide staining. PolyA + mRNA 
was converted to cDNA using the One-Step RT-PCR Kit (Qiagen) according 
to the following protocols: 
Component Volume 
RN ase free water 7.0µL 
Sx Qiagen OneStep RT-PCR Buffer 5.0µL 
dNTP Mix (containing 10mM of each dNTP) 1 .0µL 
Sx Q solution (Qiagen) 5.0µL 
Forward Primer (0.6µM) 1.SµL 
Reverse Primer (0.6µM) 1.SµL 
Qiagen One-Step RT-PCR Enzyme Mix 1.0µL 
Template mRNA (1 pg-2µg/ reaction) 3.0µL 
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The following primers were designed prior to manufacture by Geneworks 
Pty Ltd. for RT-PCR of PAX3C and PAX3D from CMM samples: 
• PAX3C (FWD) 5' gcaatttctcctggaaggga 3' 
• PAX3C (REV) 5' attgataccggcatgtgtgg 3' 
• PAX3D (FWD) 5' tgggcagtatggacaaagtg 3' 
• PAX3D (REV) 5' ggctgcgaagaccagaaac 3' 
RT-PCR cycling conditions were as follows: 
C�cle Time 
Reverse transcription 30 min 
Initial PCR activation step 15min 
3-step cycling: 
Denaturation 30 sec 
Annealing 15 sec 
Extension 15 sec 
Number of cycles: 40 
Final extension 10min 
Temperature 
50°C 
95°c 
9 4°c 
56°C 
12°c 
12°c 
Negative controls eliminating template mRNA were included in each 
RT-PCR assay. RT-PCR products were analysed by 2°/o agarose-gel 
electrophoresis and ethidium bromide staining relative to pUC19 DNA 
ladder. Gels were run at 1 10 m V for 30 minutes in TAE buffer. 
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4.1.5 Sequencing Reactions 
Using the MinElute PCR Purification Kit (Qiagen) according to 
manufacturer's instructions, 200mL Buffer PB was added to 40µL of PCR 
sample and loaded into a MinElute spin-column prior to centrifugation at 
13000 rpm for 1 minute. Following DNA binding to the spin-column matrix, 
flow-through was discarded prior to addition of 750 mL Buffer PE to the 
spin-column and further centrifugation at 13000 rpm for 1 minute. Flow­
through was again discarded prior to centrifugation for an additional 1 minute. 
DNA was eluted by addition of 10 mL Buffer EB to centre of MinElute 
membrane, stood at room temperature for 1 minute prior to centrifugation at 
13000 rpm for 1 minute. This purification method removed all PCR reagents 
and DNA fragments under 70 base-pairs long. The ABI PRISM BigDye 
Terminator Cycle Sequencing Ready Reaction Kit (PE Biosystems) was used 
to prepare and analyse sequence amplicons by the dideoxy sequencing 
method. Sequencing reactions were run using the following protocol: 
DNA (approx. 100bp) 4µL (10ng) 
Primer (Fwd or Rev) 1µL (50 ng) 
Big Dye Terminator Mix 4µL 
ddH20 1µL 
Sequencing cycling conditions were as follows: 
96° C------ 10 sec. 
50° C------ 5 sec. 
60° C------ 4 min. Repeat for 25 cycles. 
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For removal of excess dye terminators pnor to sequencmg, 
ethanol/ sodium acetate precipitation of DNA was done by addition of 2.0 rnL 
3M sodium acetate (pH 4.6) and 50rnL 95% ethanol to each completed 
sequencing reaction. Tubes were shaken, left at room temperature for 5 
minutes then centrifuged at 13000 rpm for 45 minutes. Supernatant was 
discarded before addition of 150rnL 70% ethanol and centrifugation at 13000 
rpm for 10 minutes. Supernatant was again discarded and 150 µL of 70% 
ethanol added to each pellet prior to centrifugation at 13000 rpm for 10 
minutes. Supernatants were discarded and pellets dried at 65°C. Products 
were sequenced by the DNA sequencing services at Royal Perth Hospital 
(Perth) using an ABI Prism 3730 48 capillary sequencer; sequences were 
aligned with known sequences in GenBank using the multi.align tool in the 
Angis computer program, available on GenBank. 
4.2 MURINE EMBRYO TRANSCRIPT ANALYSIS------
4.2.1 Collection of murine embryonic samples 
Wild-type ARC outbred mice were housed 1n community cages at 
Edith Cowan University, fed water and murine chow ad libitum and kept in 1 2  
hour light and dark cycles. Pregnant female mice and embryos were 
euthanised by CO2 overdose in a sealed container. Pregnancies and embryonic 
ages were timed by sight of the vaginal plug and embryos were surgically 
removed at embryonic day 1 1  (El l), E1 2.5, E15 and E20. 
Whole embryos were used to analyse Pax3 transcripts at El 1 ,  the time 
of migration of melanoblasts from neural crest to the dermis. At E1 2.5, there 
is synchronous migration of melanoblasts from the dermis to the epidermis. 
Skin could not be dissected from the embryo at this time, however, to analyse 
Pax3 transcripts, segregation of head from body of E12.5 embryos was used 
to analyse Pax3 transcripts of the developing limb, trunk and diaphragm 
musculature as compared to Pax3 transcripts of the brain. Tissues isolated 
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from E 15 and E20 embryos included whole skin, body Oess skin) and head 
Oess skin) . Skin was segregated, in particular, to examine Pax3 transcripts 
during the E15 stage of melanoblast migration into the developing hair 
placode and the E20 stage of differentiation of the melanoblast toward the 
melanin producing melanocyte. All murine embryonic tissue specimens for 
mRNA analyses were immediately snap-frozen in liquid nitrogen following 
excision and kept frozen at -70° until use. Ethical clearance for use of the 
animals was acquired through the Animal Ethics Committee of Edith Cowan 
University (project # 03-A8) . 
4.2.2 Total RNA and polyA+ mRNA Isolation 
Total RNA isolation and poly A+ mRNA purification from munne 
embryonic samples was performed as detailed in sections 4. 1 .2 and 4. 1 . 3 . 
4.2.3 RT-PCR Analysis of Pax3c/3dTranscripts 
Protocols for RT-PCR assays were as detailed in section 4.1.4. The 
following primers were designed for RT-PCR of Pax3c/ 3d from murine 
embryonic samples: 
• Pax3c (FWD) 5' gggggtagttcctcctgg 3' 
• Pax3c (REV) 5' caatcagctgtctttgccac 3' 
• Pax3d (FWD) 5' tgggcagtatggacaaagtg 3' 
• Pax3d (REV) 5' gtggaggccggaaacagg 3' 
These primers were manufactured by Geneworks Pty Ltd., Australia. 
4.2.4 RT-PCR Analysis of c-KitTranscripts 
Poly A+ mRNA was converted to cDNA using the protocol described 
1n 4.1.4. The following primers were designed for RT-PCR of c-Kit from 
murine embryonic samples: 
• mcKitF (FWD) 5' agacagacaagaggagatc 3' 
57 
• mcKitR (REV) 5' aatacaattcttggaggcga 3' 
These primers were manufactured by Geneworks Pty Ltd., Australia. 
RT-PCR cycling conditions were as follows: 
Cicle Time Temperature 
Reverse transcription 30 min 50°C 
Initial PCR activation step 15min 95°c 
3-step cycling: 
Denaturation 30 sec 94°C 
Annealing 15 sec 52°c 
Extension 15 sec 12°c 
Number of cycles: 40 
Final extension 10min 12°c 
Negative controls eliminating template mRNA were included in each RT­
PCR assay. RT-PCR products were analysed by 2% agarose-gel 
electrophoresis and ethidium bromide staining relative to pUC19 DNA 
ladder; gels were run at 110 mV for 30 minutes in TAE buffer. 
4.2.5 RT-PCR Analysis of Mitf-m Transcripts 
PolyA+ mRNA was converted to cDNA using the protocol described 
in 4.1.4. The following primers were designed for RT-PCR of Mitfm from 
murine embryonic samples: 
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• mA1ITFF (FWD) 5' taagtggtctgcggtgtc 3' 
• mA1ITFR (REV) 5' atgcctctttttcacagttg 3' 
These primers were manufactured by Geneworks Pty Ltd., Australia. 
RT-PCR cycling conditions were as follows: 
Cicle Time Temperature 
Reverse transcription 30 min 50°C 
Initial PCR activation step 15min 95°c 
3-step cycling: 
Denaturation 30 sec 94°c 
Annealing 15 sec 54°c 
Extension 15 sec 72°c 
Number of cycles: 40 
Final extension 10min 72°c 
Negative controls eliminating template mRNA were included in each RT­
PCR assay. RT-PCR products were analysed by 2°/o agarose-gel 
electrophoresis and ethidium bromide staining relative to pUC19 DNA 
ladder; gels were run at 1 10 m V for 30 minutes in T AE buffer. 
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4.3 MORINE FOLLICULAR TRANSCRIPT ANALYSIS�----
To assess the expression of Pax3c and Pax3d in murine melanoblastic 
cells during proliferation and migration throughout normal hair follicle re­
pigmentation, active synchronised hair growth (anagen) was induced in mice 
by depilation. Methods were based on those previously described by Paus et al 
(1999) as these are recognised methods used to assess gene expression during 
murine hair regrowth. 
4.3.1 Collection of Murine Skin Samples 
Wild-type C57BL/ 6 inbred mice were housed in community cages at 
. Edith Cowan University, fed water and murine chow ad libitum and kept in 12 
hr light/dark cycles. Mice were sedated with midazolam (Hyponovel, Roche) 
via intramuscular injection at a dosage of 0.1mg/kg. Using a wax/rosin 
mixture warmed to 38° , a 15x15mm area of skin was depilated at the cervical 
region of the back. At 12, 24, 36, 48 and 60 hours post depilation, mice were 
euthanised by CO2 overdose and skin samples harvested. Skin was thoroughly 
cleansed with 100% ethanol prior to being immediately snap-frozen in liquid 
nitrogen and kept at -70° until use. Ethical clearance for depilation and use of 
the animals was acquired through the Animal Ethics Committee of Edith 
Cowan University (project # 03-A8) . 
4.3.2 Isolation of Total RNA-Murine Skin Samples 
Frozen skin samples were crushed with liquid nitrogen in a mortar and 
pestle prior to addition to TriZol Reagent (Invitrogen) . Crushed tissues were 
homogenised in 1mL of TriZol per 50-100 mg of tissue using a glass-col 
homogeniser. Homogenised samples were passed several times through a 19 
gauge needle with syringe prior to addition of 1 OµL proteinase K solution 
(10mg/mL ddH20) . Solution sat at room temperature for 10 minutes prior to 
continuation of isolation procedure as described in section 4.1.2. 
60 
4.3.3 Poly A+ mRNA Purification 
PolyA + mRNA purification of 10 murine skin samples was performed 
using protocol detailed in section 4.1.3. 
4.3.4 RT-PCR Analysis of Pax3c/3dTranscripts 
RT-PCR of 10 murine skin samples for Pax3c/ Jd was performed using 
protocol detailed in section 4.2.3. 
4.3.5 RT-PCR Analysis of c-KitTranscripts 
RT-PCR of 10 murine skin samples for c-Kit was performed using 
protocol detailed in section 4.2.4. 
4.3.6 RT-PCR Analysis of Mitf-m Transcripts 
RT-PCR of 10 murine skin samples for Mitf-m was performed using 
protocol detailed in section 4.2.5. 
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4.4 IMMUNOHISTOCHEMISTRY ANALYSES -------
4.4.1 Pax3 Protein Analysis in Murine Embryogenesis 
Following surgical excision, embryos were immersed m OCT and 
frozen immediately in thawing isopentene. These were stored at -70 °C until 
further use. Frozen murine embryos were cryosectioned into 6 µm tissue 
sections at -20°C onto Superfrost Plus slides and immediately taken through 
the staining protocol as follows. 
Sections were air-dried for six hours prior to immersion in acetone at 
4 °C for 1 minute and allowed to stand at room temperature for 1 minute. 
Sections were rehydrated in Tris buffered saline for 5 minutes prior to 
incubation in phosphate buffered saline (PBS) and Triton-X100 (0.2%) for 10 
minutes. Sections were then incubated in PBS containing 3% H202 for 10 
minutes. Sections were rinsed in fresh PBS 2 times for 7 .5 minutes prior to 
incubation for 30 minutes with PBS and 10% fetal calf serum. PBS/10%fetal 
calf serum was poured off sections prior to incubation with Pax3c or Pax3d 
antibodies. These rabbit polyclonal antibodies were manufactured and kindly 
donated by Tom Barber and Johns Hopkins University; sequences of C­
terminus amino acids used for their manufacture are kpwtf for Pax3c and 
afhylkpdia for Pax3d. These primary antibodies were applied at a 1 :10 working 
dilution prior to standing overnight at 4°C. 
Sections were washed in fresh PBS 2 times for 15 minutes followed by 
incubation of secondary antibody consisting of biotinylated anti-rabbit IgG 
(DAKO LSAB2 System) for 10 minutes at room temperature. Sections were 
washed in PBS for 15 minutes prior to application of tertiary antibody 
consisting of horseradish peroxidase (HRP) linked streptavidin (DAKO 
LSAB2 System) for 10 minutes at room temperature. Following a wash in 
PBS for 15 minutes, the staining reactions were completed using 3, 3-
diaminobenzidine (DAB) substrate (Sigma Chemicals) as chromogen. Sections 
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were incubated with DAB for 2 minutes, placed in ddH20 to stop reaction 
and taken through an ethanol and xylene series (70/95/100/100/100/3X 
xylene) prior to coverslipping with DEPEX mounting medium (EMS) . 
Negative controls consisted of sections processed at the same time and in the 
same manner, however primary antibodies were eliminated. 
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5 
RESULTS 
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"Science knows of instances where an investigator was in possession of all the important facts 
yet failed to ask the right questions. " 
Emst Mayr 
5.1 mRNA ANALYSES ----------------
5.1.1 PAX3 mRNA in CMM 
Aberrant expression of P AXJ in CMM was first detected by Barr et al. 
(1999) , who found that expression levels were "notably high"; moreover, they 
described the predominant P AX3d transcript as a novel transcript. In a similar 
study, Scholl et al. (2001) reported that 77% of melanomas tested showed 
P AX3 expression while all normal perilesional skin, melanocytes and benign 
lesions tested showed no P AXJ expression. In order to analyse the relative 
expression profiles of P AX3 in CMM, metastatic CMM samples ( cytologic 
diagnosis following excision confirmed using Giemsa staining and 
immunohistochemistry) were assayed for PAXJC and PAXJD mRNA. 
Total RNA was isolated from each sample, prior to isolation of 
polyadenylated (poly A; mRNA. Poly A+ isolation of mRNA was necessary to 
ensure that products generated by RT-PCR were from mRNA rather than 
from genomic DNA as differential amplification of PAXJC from PAXJD 
utilises a 3' primer corresponding to a retained intronic sequence within the 
PAXJC sequence. Negative controls for each sample were performed by 
elimination of the reverse transcription portion of the RT-PCR reaction. 
Each sample was then analysed for both PAXJC and PAXJD transcripts by 
R T-PCR to provide a relative expression profile of these transcripts within 
each sample. Controls and RT-PCR products were then analysed and 
visualised by 2% agarose gel electrophoresis. 
In the CMM biopsies tested, 100% (5/5) showed both PAXJC and 
PAXJD expression, as was expected (Figure 5.1) .  
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5.1.2 Pax3 mRNA in Murine Embryogenesis 
To date, no published studies have identified expression of 
PAX3D/Pax3d in normal human or mouse melanocytic tissues. 
Consequently, a primary aim of the study was to investigate whether the 
Pax3d transcript is expressed during normal melanocytic development. Pax3 is 
known to alter transactivational function through alternative splicing of the 3' 
end, so it was queried whether Pax3d may be primarily utilised by muscle or 
brain cells with expression in CMM being uncharacteristic for melanocytic 
cells. Therefore, murine embryonic tissues were separately analysed as brain, 
trunk and limb skeletal muscle (herein referred to as boqy samples) and skin 
samples (where possible) to identify specific localisation of Pax3 mRNA 
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expression within brain, limb bud and skin cells; embryonic age was chosen to 
reflect key stages of melanocytic development. Samples are outlined in Table 
6. 
Table 4. Sample selection for investigation of PaxJc and Pax3d transcript 
expression in murine embryogenesis. 
� N:umber Qf samples Tiss:ue se�tiQns 
Embryonic day 11 (E11): Melanoblasts one whole 
migrate from neural crest to dermis (Mayer, 
1973) 
E12.5: Melanoblasts synchronously migrate six head, body 
from dermis into epidermis (Yoshida et al., 
1996) 
E15: Melanoblasts migrate into hair follicles nine head, body, skin 
(Hirobe, 1 984) 
E20: Visible melanin formation indicates nine head, body, skin 
melanocytic differentiation (Miiller-Rover et 
al., 2001) 
Thus, a total of 25 murine embryonic samples were assayed for Pax3c 
and Pax3d expression. Total RNA was isolated from samples prior to isolation 
of poly A+ mRNA. Again, poly A+ isolation of mRNA was necessary as 
differential amplification of Pax3c from Pax3d utilises a 3'  primer 
corresponding to a retained intronic sequence. Negative controls for each 
sample were performed by elimination of the reverse transcription portion of 
a RT-PCR prior to visualisation by 2% agarose gel electrophoresis. Each 
sample was then analysed for both Pax3c and Pax3d transcripts by RT-PCR 
and visualised by 2% agarose gel electrophoresis (this method of analysis 
provides a relative expression profile of these transcripts within each sample) . 
67 
At E11 , both Pax3c and Pax3d transcripts are expressed (Figure 5.2) . At 
this stage, whole embryos were used because it was merely necessary to show 
the presence or absence of Pax3c or Pax3d; consequently, while the Pax3d 
transcript is expressed, lineage (s) activity at this developmental stage remains 
undetermined. 
117 bp 
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At E12.5, both Pax3c and Pax3d transcripts are expressed in the head 
and body (Figure 5.3). Segregation of the skin from these embryos was 
unsuccessful as it was fragile and thin; therefore, Pax3c and Pax3d expression 
may be indicative of transcriptional activity in neural, muscle and/ or 
melanocytic lineages at this stage. It suffices to say that both transcripts are 
expressed at this stage of murine embryogenesis and that Pax3d is a 
functioning transcript. 
Figure S..1. Detection of Pax:Jc, P.add'Tramcripta in E12.5 Murlne Einbtyos. 
RT-PCR products geoei:ated from E12.5 mRNA, using exon 8 (PaxJ" and exon 9 (PaxJd) 
p� -,jsualised. on 2% ethidium bromide-stained agarose gels. Pa:Jc= PaxJ, tmnscript amplified 
(expectec:l product leogth- 117 hp); Pax3c#= PaxJd tmnsaipt amplified (expected product length- 97 hp); 
hd= heac1; bd= body; -co= negative control for primers without template mRNA; pUC= DNA ladder 
(pUC 19 digested with Hpall). 
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At E15, all tissue samples showed Pax3c and Pax3d transcript 
expression (with the exception of the skin of embryo #2) thus indicating a 
role for both transcripts in neural, muscle and melanocytic cells at this stage of 
development (Figure 5.4 ). 
F� 5,4. Detection of Psudc, Pa.ddTransctipta in Et5 Morine Embryo&, 
RT-� products generated from B15 � using exon 8 (Pa:d9 and exon 9 (Pa:dd) 
� wuilised on 2% etbidium bromide-stained aguose gels. Pa.1t:= PaxJt- ttanscrlpt amplified 
(� � �- 1 17 bp); Pax.1d=: PaxJd ttansctipt amplified (expected product length- 97 bp); 
hd=head; bd=body; ak;:skin; -co= neg-ative conuol fot prlmets without template mRNA; pUC=DNA 
laddet (pUC 19 digested with Hpall). 
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By E20, Pax3c transcript expression 1s evident m all, while skin 
primarily lacks Pax3d expression (Figure 5.5). 
PaddTramcripta in E20 Mudne Embryos. 
ted from E20 �A, using exon 8 (Pt«J9 and exon 9 (Pt«Jd) primers, 
· c-stained agarose geli. Pax.1t::;:. PIIXJ( tl:aQ&aipt amplified (expected 
PaxJd transaipt a.mi,lified (expected product length- 97 bp); hd=head; 
• control for primers without template mRNA; pUC=DNA laddet (pUC 
In summary, the Pax3d transcript is found expressed in normal murine 
embryogenesis at key stages of melanocytic development. Moreover, both 
Pax3c and Pax3d transcripts are expressed in various segregated tissue samples 
chosen to reflect brain, muscle and skin lineages. 
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5.1.3 Pax3 mRNA in Follicular Regrowth 
As the hair follicle cycles through stages of growth, regression, resting 
and shedding, pigment cells also cycle through periods of proliferation, 
migration, differentiation and apoptosis (Milller-Rover et al., 2001). Histologic 
and ultrastructural studies have demonstrated that when the hair follicle 
undergoes active growth (anagen), melanoblasts migrate out of a stem cell 
niche, proliferate, localise in the hair matrix before further proliferation and 
differentiation into mature melanocytes (Nishimura et al., 2002). 
In order to induce spontaneous anagen, depilation of C57 /BL6 
pigmented mice was carried out according to standard methods (Paus et al., 
1999). Subsequent hair growth was exploited to analyse Pax3 expression, in 
particular, to investigate generation of Pax3d transcripts in an additional 
"normal" melanocytic proliferation, migration and differentiation model. Skin 
samples were taken every 12  hours up to 60 hours post depilation, 
corresponding to proliferation and migration of melanoblasts into the 
regenerating hair placode during anagen. Two separate depilation experiments 
were performed using one mouse for each stage of 12  hour analysis, therefore 
providing a total of 10 skin samples for analysis of Pax3c and Pax3d 
expression. Prior to isolation of mRNA from the depilated skin samples, 
haematoxylin and eosin staining was performed on adjacent sections of 
depilated skin to ensure complete removal of hair sheath and associated 
melanocytes of the inner root sheath. 
Total RNA was isolated from each sample, prior to isolation of poly A+ 
mRNA. To ensure genomic DNA was not present in the isolated mRNA 
samples, negative controls for each sample were performed by elimination of 
the reverse transcription portion of a RT-PCR reaction. RT-PCR products 
were assessed by 2% agarose gel electrophoresis. Each sample was analysed 
for both Pax3c and Pax3d transcripts by RT-PCR, providing a relative 
expression profile of these transcripts within each sample. 
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In depilation experiment #1, individual samples were taken at 12-hour 
intervals up to 60 hours post depilation. In this trial, Pax3c expression was 
seen at 24, 36, 48 and 60 hours post depilation .. By contrast, Pax3d expression 
was only observed at 12 hours and then at 48 hours post depilation (Figure 
5.6). 
- 1 17  bp 
-97 bp 
Pigtue 5.G. Detection of Pax.Jc, Pa.ddTranactipta in Depilation Experiment #1 
RT-PCR products generated ftom depilated skin mRNA samples, using exon 8 (PaxJf) and exon 9 
(PaxJt!J prunen, visualised on 2% ethidium bromide-stained agatose gels. Pax.1c= PaxJe ttanscript 
amplified (expected product length- 117 bp ); Pax.'Jd= PaxJd ttanscript amplified (expected product length-
97 bp); 12, 24, 36, 48, 60 indicates 12 hour time interval ftom depilatlon; -co= negative control for primers 
without template mRNA; pUC=DNA ladder (pUC 19 digested with Hpall). 
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Depilation experiment #2 confirmed findings of experiment #1 .  Again, 
individual samples were again taken every 12 hours up until 60 hours post 
depilation. As for trial #1 ,  in trial #2 Pax3c expression was seen at 24, 36, 48 
and 60 hours post depilation and Pax3d expression was seen first at 12  hours 
and then at 48 hours post depilation (Figure 5.7). 
- 1 17  bp 
-97 bp 
In summary, the depilation experiments reiterated a role for Pax3d in 
normal melanocytic development, in this instance when coupled to hair 
follicle cycling. The Pax3c transcript was expressed in 8 : 10 samples assayed; 
the Pax3d transcript was expressed in 4: 10  samples. As melanin granules 
appear above the dermal papilla at approximately 96 hours post depilation 
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(Muller-Rover et al., 2001), Pax3c and Pax3d express10n seen 10 these 
experiments is indicative of an early role in proliferation, migration and/ or 
differentiation of melanoblasts during anagen hair growth. Furthermore, 
Pax3d expression is seen within 12 hours post depilation, prior to Pax3c 
expression in these experiments. 
5.1.4 c-.Kit mRNA in Follicular Regrowth 
Both Pax3 and c-Kit are important in melanocytic development, ·therefore, 
we tested the hypothesis that Pax3 may regulate c-Kit. Overlapping spatial and 
temporal expression of Pax3 and c-Kit in murine melanogenesis prompted 
investigation into possible concurrent expression patterns in hair follicle 
cycling. The expression pattern of c-Kit in the early stages of hair follicle 
melanogenesis was therefore assessed for correlation with the observed 
expression patterns of Pax3 in skin samples from depilation experiments. 
164 bp-
Figure S.8. Detection of cKitTranscripta in Depilation Experiments. 
RT-PCR. products generated from depilated skin mRNA samples, using ,Kit primers, visualised 
on 2% cthidium. bromide-stained agarose gels. cKit= ,Kit transcript amplified (expected product length-
164 bp); 12, 24, 36, 48, 60 indicates 12  hour time intervals for depilation; -co= negative control for 
primers without template mRNA; pUC=DNA ladder (pUC 19  digested with Hpall). 
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c-Kit expression was seen 1n 100% (10 / 10) of depilated skin samples, 
ranging from 12 to 60 hours post-depilation (Figure 5 .8) .  In both depilation 
trials, c-Kit expression is seen at 12 hours post depilation, preceding Pax3c 
· expression therefore indicating that c-Kit expression is not related to Pax3c 
expression. Consistency of c-Kit expression throughout anagen, as compared 
to varied temporal expression of Pax3d, also indicates that c-Kit expression 
may not be related to Pax3d expression. 
5.1.5 Mitf-m mRNA in Embryogenesis 
Another candidate gene thought linked to Pax3(d) transactivation was 
micropthalmia-associated transcription factor (MiifJ. Miif is one of the earliest 
genes expressed in the melanocytic lineage (Opdecamp et al., 1997) .  Like Pax3, 
Miif produces alternative isoforms that are constitutively expressed in various 
tissues, the melanocyte specific isoform being Mitf-m (Y ajima et al., 1999) . 
Pax3 has been shown to bind and transactivate the promoter region of Mitf-m 
(Watanabe et al., 1998), therefore, co-expression studies were undertaken to 
investigate a possible association between Pax3 and Mitf-m expression in 
embryogenesis. Using primers specific for the Mitf-m isoform, RT-PCR of 
murine embryonic mRNA samples (previously tested for Pax3 mRNA) was 
performed to analyse Mitf-m mRNA expression. 
The results indicate that Mitf-m is initially expressed in the E1 1 embryo, 
but is not seen in tissues of the E12.5 embryo. Expression is again apparent in 
the skin of E1 5 and E20 embryos (Figures 5.9 and 5 .10) ;  like Pax3c and 
Pax3d, Mitf-m is observed at most stages of melanocyte development (bar 
E12.5) . 
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314 bp-
314 bp-
Pig,ue 5.9. Detection of Mitf.m Transcripts in Morine Emmyoa. 
RT-PCR products generated &om Et 1 ,  E125, E15 and E20 mRN.A. using Mif-111 primen for 
melan� specific isofoaa. visualised on 2% ethidium bromide-stained aguose gels. Mitf.m= Mitf-111 
ttansaipt amplified (expected product length- 314 bp); hd=bead; bd=body; 1k=skin; -co= negative 
control for primen without template mRNA; pUC=DNA ladder (pUC 19  digested with Hpall). 
Figutt S.10. Detection of Mitf.m Tran1cripta in Morine Embtyo1. 
RT-PCR products generated &om El 1, E12.5, E15 and E20 mRNA, using Mitfm primei:s fot 
m.elanocytic specific isofonn, visualised on 2% ethidiwn bromide-stained aguose gels. Mitf.m= Mitfm 
ttansc:tipt amplified (expected product length- 314 bp); hd=head; bd=body; 1k=skin; -co= negative 
control for primers without template mRNA; pUC=DNA ladder (pUC 1 9  digested with Hpall). 
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5.1.6 Mitf-m mRNA in Follicular Regrowth 
Investigation of potential Pax3 and Mitf-m co-expression patterns was 
also undertaken with skin samples from depilation experiments. Using primers 
specific for the Mitf-m isoform, RT-PCR of depilated skin mRNA samples 
(previously tested for Pax3 mRNA) was performed to analyse Mitf-m mRNA 
expression. Results indicate varied expression of Mitf-m in depilation 
experiments with expression seen in 50% (5/10) of skin samples assayed. In 
both experiments, no Mitf-m is observed at 12 hours past depilation and varied 
expression is observed at 24, 36, and 48, hours past -depilation (Figure 5.11). 
Furthermore, Mitf-m is observed at 60 hours in both experiments confirming a 
role for Mitf-m in the maintenance of the melanocytic lineage. 
314 bp-
Figutt S.1L Detection of Mitf-m Transcripts in Depilation Experiments. 
RT-PCR products gcnemted from depilated skin mRNA samples, using Wf-111 primers for 
melanoc:ytic specific isofom1, visualised on 2% ethidium bromide-stained ag-arose gels. Mitf-m= M.if-111 
tmnscript amplified (expected product length-314 hp); 12, 24, 36, 48, 60 indicates 12 hour time intervals 
for depilatlon; -co= neg-ative control for primers without template mRNA; pUC=DNA ladder (pUC 19  
digested with HpaII). 
In summary, RNA expression analyses of Pax3c, Pax3d, c-Kit and Mitf-m 
revealed no obvious relationship between c-Kit and Pax3 expression. Mitf-m 
expression patterns within murine embryogenesis may be linked to Pax3c 
78 
expression, however further immunohistochemical co-localisation studies are 
required to investigate this possibility. The following table summarises Pax3c, 
Pax3d, cKit and Mitf-m RNA expression patterns observed throughout murine 
stages of embryogenesis and hair follicle cycling (Table 7). 
Table 5. Overview of Pax3c, Pax3d, cKit and Mitf-m Expression in Stages of 
Murine Embryogenesis. 
Pax3d Mitfm 
E1 1- Melanoblasts migrate from neural Expressed Expressed 
crest to dermis (Mayer, 1973) 
E12.5- Melanoblasts synchronously Expressed in Not expressed 
migrate from dermis into epidermis head, body 
(Yoshida et al., 1 996) 
E 1 5- Melanoblasts migrate into hair Expressed in Expressed in 
follicles (Hirobe, 1984) head, body, skin skin 
E20- Visible melanin formation indicates Expressed in Expressed in 
melanocytic differentiation (Milller-Rover head, body skin 
et al., 2001) 
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Table 6. Overview of Pax3c, Pax3d, cKit and Mitf-m Expression in Depilation 
Experiments. PD= post depilation. 
12 hr PD 
24 hr PD 
36 hr PD 
48 hr PD 
60 hr PD 
Pax3d 
Expressed in all 
samples 
Not expressed 
Not expressed 
Expressed in all 
samples 
Not expressed 
Mitfm 
Not expressed 
Expressed in 50% 
of samples 
Expressed in 50% 
of samples 
Expressed in 50% 
of samples 
Expressed in all 
samples 
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5.2 Pax3 IMMUNOHISTOCHEMICAL ANALYSE�------
5.2.1 Analysis of E12.5 Pax3 Localisation 
Yoshida et al. (1996) demonstrated that around E12.5-13.5, 
melanoblasts enter the epidermis synchronously and proliferate extensively. 
In order to examine the location of Pax3+ cells in the embryo at this stage, 
immunohistochemical staining of E12.5 frozen sections was undertaken using 
Pax3c and Pax3d specific antibodies. At the periphery of many sections, 
throughout the dermis, positive staining could be seen for Pax3c and Pax3d 
proteins, in a pattern typifying migration of melanoblasts from the dermis 
toward the epidermis during this window of time (Figure 5.12). 
Both Pax3c+ and Pax3d+ cells are most evident in the buccal region, 
vibrassal region and dorsal tail regions of the skin at E12.5, differing slightly in 
number (Figure 5.13). While Pax3c+ staining was uniform throughout the 
entire dermis of the E12.5 sections, Pax3d+ staining was confined to regions 
8 1  
of buccal and caudal dermis. Staining results of E12.5 embryos confirm that 
Pax3c and Pax3d expression demonstrated in RT-PCR analyses of head and 
body samples is linked to a role in melanocytic development at this stage. 
Superior lip 
B • 
. .  
C 
E 
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5.2.2 Analysis of Pax3 E15 Localisation 
In order to examine the location of Pax3+ cells in the embryo at this 
stage, immunohistochemical staining of E 1 5  frozen sections was undertaken 
using Pax3c and Pax3d specific antibodies. At around E1 5, a subpopulation of 
melanoblasts migrates toward the developing hair germs where they localise in 
hair follicle pigmentary units (Hirobe, 1 984) . Analysis of staining within E15  
skin sections revealed positive staining for Pax3c and Pax3d proteins at the 
periphery of all sections, throughout the epidermis (Figure 5 . 14) .  In the skin, 
there is a notable variance between Pax3c and Pax3d staining; many Pax3c+ 
cells are seen within developing hair follicles while few Pax3d+ cells are seen 
here. Moreover, Pax3d+ cells are distributed profusely throughout the 
epidermis where Pax3c+ cells are sparse. These results confirm RT-PCR 
analyses of samples demonstrating both Pax3c and Pax3d expression in 
embryos at E1 5; immunohistochemistry, however, highlights different 
expression patterns. 
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Furthermore, Pax3c+ and Pax3d+ cell staining 1s seen within the 
midbrain of the E15  embryonic sections (Figure 5. 1 5); this is significant in 
that ours is the first evidence for a role for the Pax3d transcription factor 
within the developing brain. 
igure 5.15. Immunhistchemical Staining of Pax3+ Cells in E15 Midbrain. 
Immunohistochemical staining of E15 sections using Pax3 primary antibodies and a biotin 
atreptavidin-peroxidase system visualised with DAB. Dark brown Pax3c+ (A) and Pax3d+ (B) cells 
en in the dorsal layers of the superior collicQ!us as indicated by auows. 
Positive staining 1s also seen for both Pax3c and Pax3d in the 
panniculus camosus muscle located beneath the subcutis (Figure 5 . 14) 
explaining evidence for Pax3c and Pax3d expression seen within head and 
body samples (less skin) in the RT-PCR analyses. 
5.2.3 Analysis of Pax3 E20 Localisation 
Murine epidermal melanoblasts begin to terminally differentiate at 
around E14, with subsequent pigmentation activity induced 2 days later 
(Hirobe, 1984) . Perinatally, at E20, hair follicles are characterised by initial 
melanin formation thus indicating an advanced stage of melanocytic 
differentiation. Furthermore, after birth most epidermal melanocytes, except 
those of hairless areas such as the ears and tail, undergo apoptosis (Hirobe; 
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1 984) leaving only melanoblasts and melanocytes of the hair follicles to 
produce pigmentation of the murine coat. Therefore, immunohistochemical 
staining of E20 frozen sections was undertaken using Pax3c and Pax3d 
specific antibodies in order to compare Pax3 distribution just prior to birth. 
In E20 skin, Pax3c + positive staining is greatly diminished (as compared 
to the E1 5 embryonic skin) with only few positive cells along the entire 
periphery of the skin. Positive Pax3c staining is primarily seen within the hair 
follicle above the dermal papilla and amongst the distal hair follicle epithelium 
(Figure 5. 1 6) while no Pax3d+ staining is observed in the skin (Figure 5.17). 
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85 
Moreover, in the E20 head, the midbrain shows positive staining for 
both Pax3c and Pax3d further supporting a role for Pax3d in development of 
the brain (Figure 5.18). 
In the E20 body, sparse Pax3d+ cells are seen within the peritoneal 
cavity in the region of the ileum while no Pax3c + cells are seen (results not 
shown). Pax3c+ staining is also detected in the nuclei of trunk skeletal muscle 
(Figure 5.19) and within the panniculus camosus muscle located directly 
beneath the skin (Figure 5.20) while Pax3d+ cells are not observed in these 
regions. The presence of positive cells in the midbrain and within the body 
confirms E20 embryonic RT-PCR assays demonstrating Pax3c and Pax3d 
expression in head and body (less skin) while immunohistochemical staining 
results of the skin highlight differential expression of Pax3c and Pax3d in the 
skin and support RT-PCR findings that Pax3c is expressed in murine E20 
skin while Pax3d is not expressed. 
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In summary, Pax:3 immunohistochemical staining of frozen sections 
throughout stages of munne embryogenesis reveals that Pax3d is 
constitutively expressed and appears to have distinct spatial and temporal 
expression patterns relative to Pax3c. Differences in Pax3c and Pax3d protein 
expression seen in our experiments are summarised in Table 9. 
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Table 7. Overview of Pax3 Protein Expression in Stages of Murine Embryogenesis. 
E12.5 
E15 
E20 
Pax3cf cells . . .  
sparsely distributed solely in buccal, 
vibrassal, and tail regions of the dermis. 
concentrated in the epidermis with almost 
no cells within the dermis. 
observed in the panniculus camosus. 
located in the midbrain. 
not apparent in the skin. 
sparsely distributed within the peritoneal 
cavity in the region of the ilewn. 
observed throughout the midbrain. 
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6 
DISCUSSION 
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6.1 Pax3Expression in Embryogenesis 
The impetus for this research originated due to two studies reporting 
aberrant PAX3 expression in CMM. In 1999, Scholl et al. reported that PAX3 
expression in CMM was "unambiguously confined to tumour cells and not 
detected in surrounding normal tissue, normal skin sections, or sections of 
benign lesions." Barr et al. (1999) demonstrated that the predominant P AX3 
transcript in CMM splices the eighth exon to a "previously uncharacterised 
ninth exon" thus sparking a particular interest in the possible relationship of 
this alternative transcript to tumourigenesis in CMM. 
The first objective became to assess whether the alternative 
PAX3D/Pax3d transcript is a cryptic splice form observed only in tumour 
cells or a functional transcript utilised in cell development or specification. In 
a GenBank search for P AX3 transcripts with alternative 3' ends, two 
published expressed sequence tags from a human melanocyte cDNA library 
(GenBank H82467 and H97691) were found, implying that two alternate 
transcripts are expressed in melanocytic cells. Moreover, a sequence encoding 
an identical COOH-terminal to the Pax3d transcript was found in a cloned 
quail Pax3 cDNA (GenBank AF000673). The finding of an identical COOH­
terminal region encoded by the quail Pax3 gene suggested that the Pax3d 3' 
region is conserved. Therefore, a central aim of this research became to 
determine the Pax3 transcripts expressed during normal murine melanocytic 
development and ascertain evidence of the expression of the alternative Pax3d 
transcript during normal murine embryogenesis. 
Murine embryos were assayed for both Pax3c and Pax3d mRNA and 
protein expression during embryogenesis; in particular, key stages of 
melanocytic development were analysed. Embryonic day 1 1  was chosen to 
reflect the stage when melanoblasts are known to migrate from the neural 
crest. It was not possible to isolate neural crest cells at this stage , however at 
E11, Pax3c and Pax3d transcripts are expressed in whole embryo extracts, 
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indicating an early role for both transcripts in murme embryogenesis. 
Immunohistochemical analysis of Pax3 in embryos at this stage remains to be 
analysed. 
Embryonic day 12.5 was chosen to investigate Pax3 expression at a 
point in murine development when synchronous migration of melanoblasts 
from the dermis into the epidermis is known to occur. Segregation of skin 
from these embryos was unsuccessful; therefore, mRNA Pax3c and Pax3d 
expression noted in the RT-PCR assays of head and body samples alluded to 
transcriptional activity in either neural, muscle or melanocytic lineages at this 
stage. The immunohistochemical staining for Pax3c and Pax3d proteins, 
however, showed clear evidence of their expression within the E12.5 skin; 
furthermore, no visible staining was apparent in skeletal muscle and brain. In 
the E12.5 sections, Pax3c and Pax3d positive cells are noted in the dermis 
patterned in a way resembling streams of cells "migrating" from the dermis 
toward the dermal-epidermal border. This pattern of staining was evident 
throughout the entire dermis for Pax3c+ cells, while primarily regions of the 
mouth, nose and tail showed Pax3d+ cells in the dermis. The results of these 
assays are original evidence for the conserved role of the Pax3d transcription 
factor as early as embryonic day 1 1  with explicit, yet not exclusive, roles in 
murine melanocytic development. 
At embryonic day 1 5  melanoblasts are known to migrate from the 
epidermis into developing hair follicles. At E15, all segregated tissue samples 
(head, body and skin) show Pax3c and Pax3d transcript expression (with the 
exception of one sample) thus suggesting a role for both transcripts in neural, 
muscle and melanocytic cells at this stage of murine development. 
Immunohistochemical staining for Pax3c and Pax3d proteins reveal positive 
cells located within the midbrain and panniculus carnosus muscle. These 
combined assays are original evidence for the conserved role of the Pax3d 
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transcription factor in the development of the brain and panniculus camosus 
muscle in murine development. 
In the E15 skin, Pax3c+ cells are sparsely distributed in the epidermis 
with heavy staining evident within the developing hair follicles. This is in 
contrast to Pax3d positive staining which is heavily distributed in the 
epidermis with few positive cells seen within developing hair follicles. This 
pattern of staining may indicate that Pax3c+ cells localise in the developing 
hair follicles prior to Pax3d+ cells, or that cells which successfully migrate to 
the developing hair placode subsequently express Pax3c at this stage, while 
cells that remain within the epidermis continue to express Pax3d prior to their 
migration to the hair follicle. In either case, this seemingly spatial demarcation 
between protein expression in melanoblasts at this stage is possibly related to 
functional diversity for the two transcription factors. 
Perinatally, at embryonic day 20, melanogenesis in the hair bulb has 
commenced and melanin syn thesis indicates an advanced stage of melanocytic 
differentiation. In the E20 mRNA assays, Pax3c expression is again evident in 
skin as well as in all the segregated tissue samples indicating a continued role 
for the transcription factor in the development of skin, brain and skeletal 
muscle at this stage of murine development. Pax3d expression is evident 
within the head and body samples, while skin samples lack mRNA expression 
at this stage. Immunohistochemical staining for Pax3c and Pax3d proteins 
confirm positive cells located in midbrain, thus reconfirming a role for both 
isoforms in development of the brain. While Pax3c proteins are evident in 
skeletal muscle and panniculus camosus, Pax3d positive cells are evident in 
the region of the ileum again supporting a spatial demarcation of protein 
expression that may be related to functional diversity. Finally, Pax3c positive 
cells are observed in developing hair follicles proximal to the dermal papilla; 
whereas, Pax3d positive cells are not stained within the epidermis or hair 
follicles. This difference in protein expression between Pax3c and Pax3d 
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within the E20 skin further supports the notion of a complex regulaton of 
melanocytic development through use of temporally expressed Pax3 
alternative transcripts. 
Finally, it may be significant that Pax3d expression is not detected 
within normal murine melanocytes at and from E20 onwards (unpublished 
observations) . These results clearly demonstrate a conserved role for the 
Pax3d transcription factor in the earfy development of the melanoblast, prior 
to differentiation and the cellular capability for synthesis of melanin. 
6.2 Pax3 Expression in Melanogenesis 
Demonstration of a conserved role for Pax3d in the early stages of 
murine embryonal development prompted further investigation into specific 
expression of the isoform during the processes of melanoblast proliferation 
and migration during induced hair regrowth. In adult skin, following 
depilation, melanocytic stem cells of the hair follicle are known to proliferate, 
migrate to a region proximal to the dermal papilla and differentiate in order to 
produce melanin for the new hair (Nishimura et aL, 2002) . Using a reliable 
time-scale for the strict coupling of melanogenesis to active hair regrowth 
(anagen) ,  depilation experiments investigated Pax3c and Pax3d expression as 
melanoblasts undergo anagen induced proliferation, migration and 
differentiation within the hair follicle. 
Following depilation, the first melanin pigments are visible within 96 
hours. Knowing that Pax3d has an early role in the melanoblast, prior to 
melanin production, skin assays were conducted every 12 hours past induction 
of regrowth to focus on early events of anagen. It should be reiterated that, in 
murine skin following successful depilation, the only melanocytic cells 
remaining in the skin are those of the follicular stem cell niche; therefore, 
analyses of Pax3 expression within the samples gives an indication of mitotic 
and post-mitotic melanocytic events in the early stages of melanogenesis. 
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In the depilation experiments, Pax3 transcripts exhibit differential 
expression patterns during anagen lending further insight into their possible 
roles in melanogenesis. For example, Pax3c is initially expressed at 24 hours 
and is continuously expressed thereafter (up to 60 hours) while Pax3d is 
expressed solely in the period up to 12  hours past depilation and within the 
36-48 hour post depilation period. Using the time-scale of Muller-Rover et al. 
(2001), follicular transition from resting state (telogen) to anagen occurs 
around 24 hours following depilation. Therefore, expression of Pax3d within 
the 12-hour period, much earlier than anagen induction, may indicate a role 
for this transcript in the proliferation of stem cells (Nishimura et al., 2002) 
within the follicle. It should be noted that depilation induces a short healing 
response immediately thereafter; however, mRNA assays of wounded and 
healing murine skin do not demonstrate Pax3d expression (unpublished 
observations). Furthermore, Pax3d is also expressed within the 36 to 48 hour 
post depilation period as the follicle continues through the early stages of 
anagen. Again, this controlled temporal expression may be related to a 
secondary wave of melanoblast proliferation as progeny cells of the stem cell 
population undergo further mitosis (Nishimura et al., 2002) prior to 
differentiation into pigmented melanocytes. If Pax3d expression seen in these 
experiments is linked to melanoblast proliferation, this could be an important 
link to the retention of proliferative capacity in CMM as compared to benign 
naevi (which lack Pax3d expression). 
An alternate hypothesis may be that observed Pax3d expression is 
linked to migration of melanoblasts, initially in the 12 hours post depilation 
period as stem cells migrate from the niche prior to mitosis and then again 
between 36  to 48 hours post depilation as post mitotic cells migrate from the 
bulge area toward the dermal papilla. In our murine embryonic mRNA assays, 
Pax3d expression is demonstrated at all times of melanoblast migration; 
therefore, supporting this hypothesis. If then, Pax3d expression has a role in 
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melanoblast migration, this could be an important link to the highly metastatic 
capabilities of CMM. 
Conversely, in the 12-hour period past depilation, Pax3c expression is 
not demonstrated. This lack of expression indicates that Pax3c may not have a 
role in the events prior to anagen induction. Moreover, Pax3c expression 
directly correlates to the onset of anagen at 24 hours and continues through 
anagen until the onset of melanin production. This is not unexpected, 
however, as Pax3 is known to regulate genes involved in melanin synthesis, 
such as Mitf-m and tyrosinase-related protein-1 (Galibert et al., 1999) . Finally, 
it should be noted that in the 36 to 48 hour period post depilation, both Pax3c 
and Pax3d transcripts are concurrently expressed within the samples. Further 
studies are required to investigate concurrent intracellular Pax3c and Pax3d 
expression in order to gain insight into possible dosage effects for the two 
transcription factors and their individual and specific roles. Such experiments 
would include in situ hybridisation with transcript specific probes followed by 
CHIP (Chromosomal Hybridisation Immunoprecipitation) assays to 
determine transcript specific target gene sequences. 
6.3 Correlation Studies of Pax3 and c-Kit Expression 
Another objective of the research was to link aberrant Pax3c and Pax3d 
transcript expression in CMM to regulation of downstream target genes. c-K# 
and Miif-m were chosen as potential targets regulated by Pax3c and Pax3d (in 
particular) as c-Kit and Miif-m have key roles in melanocytic cell development. 
c-Kit became an important candidate for investigation as c-Kit expression is 
downregulated in CMM and Pax3 is a known gene repressor. Furthermore, 
analysis of the c-Kit promotor element sequence revealed potential binding 
sites for Pax3 transcription factors. Finally, mutations in the c-Kit locus of the 
mouse result in failure of stem cell populations to migrate and/ or proliferate 
effectively due to loss of the tyrosine kinase receptor (Geissler et al., 1988) . As 
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our previous experiments had shown an early role for Pax3d in melanogenesis, 
possibly in proliferation and/ or migration of melanocytic stem cells, the 
possibility of aberrant Pax3d downregulation of c-Kit in CMM was proposed 
and expression therefore investigated. 
mRNA analyses of c-Kit expression in murine embryogenesis was not 
undertaken, however, as the c-Kit encoded transmembrane tyrosine kinase 
receptor for stem cell factor (SCF) is required for normal hematopoiesis, 
melanogenesis, gametogenesis (Geissler et al, 1988) and development of the 
smooth musculature of the gastrointestinal tract (Huizinga et aL,1995). Thus 
detection of c-Kit mRNA would be expected in all embryonic mRNA assays 
and be inconclusive. It was decided, rather, that investigation of c-Kit 
expression in the depilation model would provide a more conclusive model 
for study of melanogenesis. In the depilation experiments, c-Kit expression is 
seen in all time periods, immediately following depilation and throughout 
anagen hair regrowth. These results allow us to conclude that c-Kit expression 
is not linked to Pax3c expression; its expression both precedes and continues 
together with that of Pax3c. Furthermore, c-Kit expression is concurrent with 
Pax3d expression early in anagen while loss of Pax3d expression during a 36 
hour period in which c-Kit continues to be expressed certainly negates 
evidence of c-Kit downregulation by Pax3d These results clearly indicate a 
lack of direct correlation between the Pax3 and c-Kit genes in our murine 
melanogenesis model and allow us to conclude that aberrant PAX3D 
expression does not contribute to the progression of CMM through 
repression of the c-KI.T gene. 
6.4 Correlation Studies of Pax3 and Mitf-m Expression 
It was important to correlate the expression of Pax3 and Miif-m in 
melanogenesis as Pax3 is known to synergistically up-regulate Miif-m together 
with Sox10 (Potter£ et aL, 2000). In the embryonic mRNA assays and depilated 
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skin samples tested, where Miif-m expression 1s demonstrated, Pax3c 
expression is seen as well (1 8/19 samples). However, in the E1 2.5 embryo 
Miif-m expression is not detected while Pax3c expression is. In the least, this 
result indicates that while Miif-m expression may be reliant on Pax3c to initiate 
expression, Pax3c expression is not solely required for maintenance of Miif-m 
expression. Finally, no apparent correlation is evident between Miif-m and 
Pax3d expression in our experiments as both inverse and overlapping 
expression is randomly seen in embryogenesis and early anagen hair re­
growth. While a double dosage effect due to concurrent PAX3C and PAX3D 
expression such as is seen in CMM mqy effect MITF-M upregulation, these 
results allow us to conclude that aberrant PAX3D expression does not solely 
contribute to the progression of CMM through transactivation of MITF-M 
6.5 PAX1Expression in CMM 
The hypotheses that aberrant P AX3 expression is linked to disruption 
of normal c-l(jt or Miif-m expression in CMM are null; however, our study has 
clarified significant aspects of P AX3 / Pax3 expression in normal melanocytic 
cells therefore providing a greater framework for investigations of the role of 
PAX3 in the tumouricity of melanocytes seen in CMM. To begin with, the 
P AX3 / Pax3 gene is known to play a role in the early morphogenesis of the 
embryo being informally referred to as a "developmental control gene"; it is 
currently thought that terminal cellular differentiation follows downregulation 
of the P AX3 / Pax3 gene. Our study has supported this notion as we saw Pax3 
mRNA expression in murine skin ceasing at embryonic day 20. Therefore, the 
re-expression of this developmental control gene in metastatic CMM biopsies, 
primary CMM tumours and melanoma cell lines (page 7 4, Scholl et al; 1999; 
Barr et al; 1999) may be theorised as a consequence of three cellular 
circumstances. 
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Firstly, re-expression of P AXJ in CMM may be a consequence of 
aberrant transcriptional regulation by its upstream genes. A known regulator 
of PAXJ transcription, N-Myc is found expressed in CMM (Harris et al., 
2002; Bauer et al., 1990; Shin et al., 1987). Another P AXJ regulator, Tead2, is 
not found expressed in CMM (Milewski et al., 2004), therefore, future 
experiments are required to examine correlations between N-Myc and P AXJ 
in CMM to determine whether P AXJ upregulation is a consequence of 
upstream gene targeting. 
Secondly, P AXJ re-expression may be a consequence of the neoplastic 
melanocyte, once perturbed by a mutagenic event, undergoing a series of de­
differentiation steps, taking it back to a stem cell state. Indeed, Mark Keating 
and his colleagues at Harvard Medical School in Boston, Massachusetts, have 
previously described a way to induce the de-differentiation of cells through 
genetic manipulation (Odelburg et al., 2000). Many CMM pathologists theorise 
that de-differentiation occurs within one or several melanocytes located in a 
nest of atypical naevi which ultimately results in malignancy. This being the 
case, however, it would seem that the probability of finding some PAXJ 
expression within benign biopsies would exist (and in fact increase with an 
increase in naevi numbers) as random naevi cells progressively de-differentiate 
through devlopmntal stages and re-express PAXJ. However, Scholl et al 
(1999) saw P AXJ expression strictly limited to cancerous melanocytes; they 
saw no P AXJ expression in normal perilesional skin or benign naevi samples . 
This leads to the possibility that a third oncogenic event causes the re­
expression of P AXJ in CMM. In our depilation experiments, Pax] re­
expression in adult murine skin is seen with the induction of anagen hair 
regrowth (almost certainly) related to proliferation or migration of 
melanoblasts or quiescent melanocytic precursor cells as they repopulate hair 
follicles. If induced melanocytic apoptosis, such as is seen with excessive UV 
exposure, leads to cell replacement from a stem cell population, perhaps 
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subsequent mutagenesis of mitotic or post-mitotic replacement cells occurs in 
CMM resulting in cell "suspension" at a stage in which P AX3 expression is 
typical. 
In any case, several significant points have been raised that require 
further investigation. For example, is the clinical finding of PAX3 mRNA 
expression in skin (the PAX3D isoform in particular) valid as a tumour 
marker for CMM malignancy? Does the expression of PAX3 occur in 
serological studies of CMM patients and if so, does this clinically indicate 
CMM metastates? Finally, if PAX3 expression tightly correlates with the 
undifferentiated melanoblast cell state as we saw in our study, would 
inactivation of the gene be sufficient to induce sustained regression of CMM 
due to ensuing differentiation of tumour cells into melanocytes? 
In conclusion, future studies of the CMM phenotype would benefit 
from continued investigation of gene expression patterns, particularly those 
involved in cell proliferation and migration (such as PAX3) during embryonal 
patterning and development. As we continue to uncover the cellular events 
that take place during the transformation of the undifferentiated stem cell to 
the terminally differentiated adult cell, we may discover key players 
responsible for the propagation of neoplastic cell properties. 
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